

AD_____

AWARD NUMBER: W81XWH-08-1-0076

TITLE: Articular Cartilage Repair through Muscle Cell-Based Tissue Engineering

PRINCIPAL INVESTIGATOR: Johnny Huard, Ph.D.

CONTRACTING ORGANIZATION: Children's Hospital of Pittsburgh
Pittsburgh, PA 15224

REPORT DATE: March 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 March 2010		2. REPORT TYPE Annual		3. DATES COVERED 1 Mar 2009 – 28 Feb 2010	
4. TITLE AND SUBTITLE Articular Cartilage Repair through Muscle Cell–Based Tissue Engineering			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-08-1-0076		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Johnny Huard, Ph.D. E-Mail: jhuard@pitt.edu			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Children's Hospital of Pittsburgh Pittsburgh, PA 15224			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Using the modified preplate technique, we have isolated a population of early myogenic progenitor cells from postnatal skeletal muscle that display stem cell characteristics. We have shown that these 'muscle-derived stem cells' (MDSCs) can differentiate toward myogenic, osteogenic, chondrogenic, neurogenic, and hematopoietic lineages. Specifically, MDSCs cultured in chondrogenic medium can undergo chondrogenic differentiation in vitro, and MDSCs delivered to osteochondral defects display good cell survival and can differentiate into chondrocytes that improve the healing of articular cartilage. We also have observed that bone morphogenetic protein 4 (BMP4) promotes chondrogenic differentiation of MDSCs in vitro and in vivo and that this cytokine can trigger chondrogenic differentiation of other populations of muscle-derived cells, including myoblasts (late myogenic progenitor cells) and fibroblasts. The proposed project will investigate the use of these populations of muscle-derived cells as novel cell sources for articular cartilage repair in osteochondral defects created in nude rats. We will investigate the in vitro chondrogenic potential of various populations of mouse muscle-derived cells (fibroblastic cells and early and late myogenic progenitor cells) expressing BMP4 and determine the regenerative capacity of these cells after implantation in rat articular cartilage defects. We then will explore the relative contributions of these muscle-derived cells' long-term proliferation, survival, and self-renewal to their regenerative capacity after transplantation into the cartilage defects (Technical Objective #1). Next, we will determine the contributions of angiogenesis and scar tissue formation to the regenerative capacity of the muscle-derived cells and to the overall quality of the cartilage generated within the treated osteochondral defects (Technical Objective #2). This project will increase our understanding of the basic biology of muscle cell populations and their possible role in chondrogenic regeneration, and may lead to the development of new techniques to improve cartilage regeneration via the transplantation of muscle-derived cells. Technical Objective #1: Evaluate different fractions of cells obtained from mouse skeletal muscle to identify the cell population with the greatest chondrogenic potential and the greatest capacity for cartilage regeneration. <i>Hypothesis: Different populations of cells obtained from skeletal muscle, when transduced to express bone morphogenetic protein 4 (BMP4), will exhibit different capacities for cartilage regeneration.</i> Technical Objective #2: Determine the relative contributions of angiogenesis and fibrosis on the capacity of muscle-derived cells to regenerate articular cartilage. <i>Hypothesis: The promotion of angiogenesis and the prevention of fibrosis will improve the persistence and quality of regenerated cartilage.</i> Relevance: This project will increase our understanding of the basic biology of muscle cell populations and their possible role in chondrogenic regeneration, and may lead to the development of new techniques to improve cartilage regeneration via the transplantation of muscle-derived cells.					
15. SUBJECT TERMS Articular Cartilage Repair, Fibrocartilage prevention, Muscle-derived Stem Cells, BMP-4, VEGF, Angiogenesis, sFLT-1					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 51	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

4) Articular Cartilage Repair through Muscle Cell–Based Tissue Engineering	
A) Introduction.....	5
B) Body.....	5
C) Key Research Accomplishments.....	10
D) Reportable Outcomes.....	10
E) Conclusions.....	11
F) Appendices.....	11
5) Appendices (1-5).....	13

**Articular Cartilage Repair through Muscle
Cell-Based Tissue Engineering
(Johnny Huard)
Contract #: W81XWH-08-0076**

Introduction

Using the modified preplate technique, we have isolated a population of early myogenic progenitor cells from postnatal skeletal muscle that display stem cell characteristics. We have shown that these ‘muscle-derived stem cells’ (MDSCs) can differentiate toward myogenic, osteogenic, chondrogenic, neurogenic, and hematopoietic lineages. Specifically, MDSCs cultured in chondrogenic medium can undergo chondrogenic differentiation *in vitro*, and MDSCs delivered to osteochondral defects display good cell survival and can differentiate into chondrocytes that improve the healing of articular cartilage. We also have observed that bone morphogenetic protein 4 (BMP4) promotes chondrogenic differentiation of MDSCs *in vitro* and *in vivo* and that this cytokine can trigger chondrogenic differentiation of other populations of muscle-derived cells, including myoblasts (late myogenic progenitor cells) and fibroblasts. The proposed project will investigate the use of these populations of muscle-derived cells as novel cell sources for articular cartilage repair in osteochondral defects created in nude rats. We will investigate the *in vitro* chondrogenic potential of various populations of mouse muscle-derived cells (fibroblastic cells and early and late myogenic progenitor cells) expressing BMP4 and determine the regenerative capacity of these cells after implantation in rat articular cartilage defects. We then will explore the relative contributions of these muscle-derived cells’ long-term proliferation, survival, and self-renewal to their regenerative capacity after transplantation into the cartilage defects (**Technical Objective #1**). Next, we will determine the contributions of angiogenesis and scar tissue formation to the regenerative capacity of the muscle-derived cells and to the overall quality of the cartilage generated within the treated osteochondral defects (**Technical Objective #2**). This project will increase our understanding of the basic biology of muscle cell populations and their possible role in chondrogenic regeneration, and may lead to the development of new techniques to improve cartilage regeneration via the transplantation of muscle-derived cells.

Relevance: This project will increase our understanding of the basic biology of muscle cell populations and their possible role in chondrogenic regeneration, and may lead to the development of new techniques to improve cartilage regeneration via the transplantation of muscle-derived cells.

Body:

1) Technical Objectives:

Technical Objective #1: Evaluate different fractions of cells obtained from mouse skeletal muscle to identify the cell population with the greatest chondrogenic potential and the greatest capacity for cartilage regeneration.

Hypothesis: Different populations of cells obtained from skeletal muscle, when transduced to express bone morphogenetic protein 4 (BMP4), will exhibit different capacities for cartilage regeneration.

Technical Objective #2: Determine the relative contributions of angiogenesis and fibrosis on the capacity of muscle-derived cells to regenerate articular cartilage.

Hypothesis: The promotion of angiogenesis and the prevention of fibrosis will improve the persistence and quality of regenerated cartilage.

Progress to Date (3-1-08 to 2-28-10):

- 1) It was observed that fibrogenic cells residing in the fascia (fascia-derived cells [FDCs]) in the skeletal muscle are chondrogenic progenitor cells. By definition, the fascia of skeletal muscle is epimysium that covers the entire body of skeletal muscle. We hypothesized that cells located in endomysium and perimysium also possess chondrogenic potential; however, physically separating the endomysium and perimysium tissues from skeletal muscle is too difficult to be accomplished. Since endomysium and perimysium tissues are contained in the skeletal muscle, muscle derived cells (MDCs) would contain cells from endomysium and perimysium as well as other populations of cells. The characteristics and chondrogenic differentiation of MDCs have been investigated and human FDCs have also been examined. Characterization of MDCs demonstrated that they contain at least two populations of cells, FDCs and a population of myogenic cells. Chondrogenic differentiation displayed by muscle derived cells (MDCs) implies that either FDCs, a population of myogenic cells, or both MDCs and FDCs have chondrogenic potential. Mixtures of FDCs and rat L6 myoblasts demonstrated FDCs are the chondrogenic progenitor cell fraction of MDCs, but the myogenic cell fraction of MDCs plays little role in chondrogenesis. Findings about rat FDCs are also supported by the positive chondrogenic differentiation displayed by human FDCs. **(Refer to Appendix 1 [Abstract])**

Intramuscular injection of bone morphogenetic protein (BMP) has been shown to induce ectopic bone formation. As in developmental bone formation, a chondrogenic phase is typically observed in this process, which suggests that there may exist a chondrogenic sub-population of cells residing in skeletal muscle. Identification and isolation of this population could yield an important cell source for cartilage tissue engineering. Two prospective cell populations were isolated from rat skeletal muscle: fascia-derived cells (FDCs) extracted from gluteus maximus muscle fascia and muscle-derived cells (MDCs) isolated from the muscle body. Both were investigated for their cell surface marker profile (flowcytometry analysis), proliferation rate, and myogenic and chondrogenic potentials. The majority of FDCs expressed mesenchymal cell markers (CD29, CD59, and CD90) but not endothelial cell markers (CD34, CD31, CD144, vWF, Flk-1 and CD146). FDCs underwent chondrogenic differentiation after BMP-4 treatment in vitro, but not myogenic differentiation when cultured in myogenic differentiation medium. Sorting on the basis of CD29 and CD146 expression demonstrated that chondrogenic potential correlated poorly with CD29 expression and negatively with CD146. In fact, unsorted FDCs demonstrated significantly higher chondrogenic potential as well as proliferation rates than all other sub-populations studied. Although MDCs were similar to FDCs in term of cell surface marker profile and chondrogenic potential, they expressed the myogenic cell marker desmin and readily underwent myogenic differentiation in vitro. However, this result is likely confounded by the presence of FDC-like cells residing in the muscle peri- and endomysium. To clarify the role of muscle derived myogenic cells in chondrogenesis, mixed pellets varying ratios of FDCs and L6 myoblasts were formed and studied for chondrogenic potential. Results suggest that myoblasts did not participate in chondrogenesis. Further studies of human FDCs demonstrated the presence of similar cell displaying a low myogenic potential and capable of chondrogenesis. From this study we conclude that non-myogenic cells residing in the fascia of skeletal muscle have chondrogenic potential and may represent a novel cell donor source for cartilage regeneration and repair. **(Manuscript under preparation, Entitled: Identification and characterization of chondrogenic progenitor cells in post natal skeletal muscle: the role of fascia derived cells in chondrogenesis)**

- 2) We explored possible differences in muscle derived stem cell (MDSC) chondrogenic differentiation in vitro and articular cartilage (AC) regeneration in vivo between murine male MDSCs (M-MDSCs) and female MDSCs (F-MDSCs). Three different populations of M- and F-MDSCs obtained via a modified preplate technique, were compared for their in vitro chondrogenic potential using pellet culture. The cells with or

without retroviral transduction to express bone morphogenetic protein 4 (BMP4) were assayed. The influence of both the expression of stem cell markers (stem cell antigen 1, SC-1) and the *in vitro* expansion level on the chondrogenic potential of M- and F-MDSCs was also determined. Lastly, BMP4-transduced M- and F-MDSCs were applied to a full-thickness AC defect of a nude rat femur. In addition to qualitative macroscopic examination, a histological grading scale of Safranin O-fast green staining was used to evaluate the quality of the repaired tissue.

Our results indicate that with and without BMP4 gene transduction, M-MDSCs produced significantly larger pellets with a richer extracellular matrix when compared to F-MDSCs. Although SC-1 purification influences the chondrogenic potential of MDSCs, especially M-MDSCs, it appears that long term culturing does not influence the chondrogenic potential of M-MDSCs, but does influence F-MDSCs. *In vivo* macroscopic and histological evaluations demonstrate that M-MDSC repair AC defects in a more effective manner than F-MDSCs, at all time points tested. **(Refer to Appendix 2, Matsumoto T, et al. A&R 2008)**

- 3) We investigated the effect of VEGF stimulation and the effect of blocking VEGF with its antagonist, sFlt1, on chondrogenesis using skeletal muscle-derived stem cells (MDSCs). The direct effect of VEGF on the *in vitro* chondrogenic ability of mouse MDSCs was tested using a pellet culture system followed by quantitative real time PCR and histological analyses. Next, the effect of VEGF on chondrogenesis within the synovial joint was tested using genetically engineered MDSCs implanted into the rat osteochondral defect. In this model, MDSCs, transduced with a retroviral vector to express BMP4, were co-implanted with MDSCs transduced to express either VEGF or sFlt1 (a VEGF antagonist) to provide a gain- and loss-of VEGF function experimental design. Histological scoring was used to compare cartilage formation among the treatment groups.

Hyaline-like cartilage matrix production was observed in both VEGF-treated and VEGF-blocked (sFlt1-treated) pellet cultures, but real-time PCR revealed that sFlt1 treatment improved the expression of chondrogenic genes in MDSCs that were stimulated to undergo chondrogenic differentiation with BMP4 and TGF- β 3. *In vivo* testing of articular cartilage repair showed that VEGF-transduced MDSCs caused an arthritic change in the knee joint, and sFlt1 improved the MDSC-mediated repair of articular cartilage, compared to BMP4 alone. **(Refer to Appendix 3, Kubo S, et al. A&R 2009)**

- 4) Osteoarthritis (OA), a chronic degenerative joint disorder worldwide and characterized by articular cartilage destruction and osteophyte formation, affects over 40 million individuals in the United States alone. Stem cells are attractive because of their superior capacity for self renewal, proliferation, and survival post-implantation. Several studies have suggested that stem cells can undergo chondrogenesis and repair articular cartilage in experimental cartilage injury models, including studies using muscle derived stem cells (MDSCs). We have already reported that bone morphogenetic protein 4 (BMP4) transduced MDSCs improve cartilage regeneration in the *in vitro* pellet culture and the *in vivo* cartilage defect model. The control of angiogenesis such as using sFlt1, vascular endothelial growth factor (VEGF) antagonist, during the chondrogenic differentiation of stem cells is also an important issue to consider especially for the persistence of the regenerate cartilage. Based on these backgrounds, the series of experiments is designed to clarify the therapeutic efficacy of BMP4 and sFlt1 transduced MDSCs for the repair of articular cartilage after OA.

Macroscopic and histological evaluation of the joint: *In vivo* testing of articular cartilage regeneration showed macroscopically and histologically that VEGF transduced MDSCs prevented but sFlt1 improved the BMP4-mediated MDSC regeneration of articular cartilage compared to the BMP4 alone, as confirmed by histological scores.

Contribution of MDSCs in cartilage regeneration and repair: Double IHC of Col2 and GFP or β -gal demonstrated that VEGF transduced MDSCs prevented but sFlt1 improved chondrogenic differentiation of MDSC and intrinsic chondrogenesis, compared to BMP4 alone.

Chondrocyte apoptosis and proliferation analyses: TUNEL stain and BrdU as say demonstrated that sFlt1-transduced MDSCs, unlike VEGF expressing cells, lead to less apoptosis and more proliferation compared to B4 alone.

Mixed pellet culture: In vitro mixed co-culture showed BMP4 treated group produced significantly larger pellets with hyaline cartilage-like matrix production than all other groups, confirmed by the chondrogenic differentiation capacity of MDSCs using qPCR and qIHC of Col2 and GFP or β -gal. FISH showed no fusion between OA chondrocytes and MDSCs and higher intrinsic chondrogenesis in BMP4 treated group.

Separated pellet culture: In vitro separated co-culture showed BMP4 treated group produced significantly larger pellets with hyaline cartilage-like matrix production than all other groups. (Refer to **Appendices 4 and 5, Matsumoto T, et al. Arthritis Rheum, 2009**).

- 5) Over the past year we have continued to investigate the optimal cell types for chondrogenic repair and regeneration and also have been investigating the mechanisms by which these cells promote superior regeneration. Over the past number of years it has become increasingly clear that the role of the donor cells participation in the repair process is not fully elucidated. In fact, in numerous animal models we have shown that the implantation of BMP4 expressing MDCs improves AC repair; however, the repair process is mediated primarily by the chemo-attraction of host cells. Therefore, we have started to more closely analyze these chemo-attracted host derived cells that appear at the injury site after MDC implantation. We want to determine the tissue of origin of the host cells that participate in the AC regeneration processes and have begun preliminary experiments designed to determine if the host cells could originate from the bone marrow or possibly the intra-articular synovial tissue. We are planning to investigate the role that donor MDC survival plays in the AC repair process even though the donor cells do not actively participate in chondrogenic differentiation but instead seem to vigorously chemo-attract host cells which are the primary cell source for the newly regenerated AC tissue. To this end we plan to investigate approaches to improve cell survival and the contribution that the donor cells play in the repair process. This is important since OA typically affects older patients and the host cells of aged patients may have a reduction in their tissue regenerative potential. To date we have preliminary results that compare the cartilage regenerative ability of the MDCs in synovectomized rats that have had an OA injury created with MIA, and compared them to rats with intact synovial membranes. The MDCs that were intracapsularly injected had half of the cells transduced with sflt-1 and the other half transduced with BMP4, which was the best transduction regime determined previously (**Appendices 1 and 4**). The cells were also transduced with either GFP or LacZ to track the fate of the donor cells. Briefly, the study methodology that we followed was: 1) Rat OA models were created using MIA, 2) Two weeks after MIA injection a synovectomy was performed in half of the rats

FIGURE 1




Macroscopic evaluation (4W)
(Treated with sFlt1/BMP4-MDSC)

as previously described [Miyamoto A, et al. *The role of the synovium in repairing cartilage defects. Knee Surg Sports Traumatol Arthrosc.* 200], 3) Three days after surgery 5×10^5 MDCs were injected (50:50 sflt-1:BMP4 transduced), 4) Four weeks after MDC injection the rats were sacrificed and their knee joints assessed. **Figure 1** shows a macroscopic evaluation of the two groups. Macroscopic evaluation of the synovectomy(-) group showed

well-healed articular surfaces, some parts of the joints included osteophyte formation. However, the synovectomy(+) group showed marked arthritis including synovial hypertrophy and osteophyte formation.


Histologic assessment demonstrated that Safranin O-positive hyaline-like cartilage was present in the synovectomy(-) group. However, Safranin O-positive hyaline-like cartilage was less prominent in the synovectomy(-) group (**Figure 2**).

FIGURE 2



A previously described histological grading scale was used to evaluate the quality of the repaired tissue. Four weeks after transplantation, the total score in the synovectomy(-) group was significantly lower than that in the synovectomy(+) group. Note that a lower score in this grading scale represents better cartilage (synovectomy(-) group, 5.2 ± 1.0 , synovectomy(+) group, 11.0 ± 1.7 , $P < 0.05$, respectively) (**Figure 3**).

FIGURE 3



These preliminary results strongly support the fact that some factor emanating from the synovium is essential for proper regeneration of OA injured articular cartilage. More investigation is necessary to determine exactly how the synovial tissue is participating in the repair process. It could be both the deployment of cells from the synovial tissue that actually participate in the remodeling of the AC and/or the paracrine release of essential

factors that aide in the healing process and potentially attract other cell types from the host. These results are being included in a paper currently under preparation.

Key Research Accomplishments to date

- Demonstrated that MDCs contain FDCs and a population of myogenic cells.
- Demonstrated that MDCs possess lower chondrogenic potential than FDCs.
- Demonstrated that non-myogenic cells residing in the fascia of skeletal muscle have chondrogenic potential and may represent a novel cell donor source for cartilage regeneration and repair.
- Demonstrated that Male MDSCs have a greater chondrogenic potential than Female-derived MDSCs
- Demonstrated that VEGF inhibits the chondrogenic potential of BMP4 transduced MDSCs
- Demonstrated that sFLT improves chondrogenic potential of BMP4 transduced MDSCs and inhibits apoptosis.
- Demonstrated that sFLT /BMP4 transduced MDSCs were superior to MDSCs transduced with only BMP4 or VEGF and BMP4 at chondrogenic regeneration after osteoarthritis was induced in rats
- Demonstrated that Human FDCs showed more fibrogenic staining and strong chondrogenic potential.
- Demonstrated that an intact synovium is essential for the proper healing of OA injured articular cartilage.
- Demonstrated that a Human Cell counter-part to the murine MDSCs were capable of differentiating toward a chondrogenic lineage and form articular cartilage.

Reportable Outcomes

1. **Li, GH; Zheng, B; Meszaros, LB; Corsi, KA; Usas, A; Huard, J.** Identification and Characterization of Chondrogenic Progenitor Cells in Adult Skeletal Muscle. Orthopaedic Research Society Annual Meeting Feb 2009 (Abstract). (**Appendix 1**) Manuscript is in preparation.
2. **Matsumoto T, Kubo S, Meszaros L, Corsi K, Cooper G, Li G, Usas A, Osawa A, Fu F, Huard J.** The influence of sex on the chondrogenic potential of muscle-derived stem cells. A&R 2008 Dec; **58(12)3809-3819. (Appendix 2)**
3. **Kubo S, Cooper G, Phillippi J, Corsi K, Usas A, Li G, Freddie F, Huard J.** Blocking VEGF with sFlt1 improves the chondrogenic regeneration capacity of skeletal muscle-derived stem cells. A&R 2009 Jan; 60(1):155-165. (**Appendix 3**)
4. **Matsumoto, T ; Cooper, GM; Gharaibeh, B; Meszaros, L; Li G; Usas A; Fu, FH; Huard, J.** Cartilage Repair after Osteoarthritis through Intra-articular Injection of Muscle Stem Cells Expressing BMP4 and sFlt1. Orthopaedic Research Society Annual Meeting Feb 2009 (Abstract). (**Appendix 4**)
5. **Matsumoto T, Cooper G, Gharaibeh B, Meszaros L, Li G, Usas A, Fu F, Huard J.** Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. **Arthritis Rheum**; Published Online: Apr 29 2009 (p 1390-1405), PMID: 19404941 [PubMed - indexed for MEDLINE]. (**Appendix 5**)
6. **Bo Zheng, Guangheng Li, Bridget M Deasy, Jonathan B Pollett, Bin Sun, Lauren Drowley, Burhan Gharaibeh, Arvydas Usas, Alison Logar, Bruno Peault, Johnny Huard.** Clonal Analysis of Human Myoendothelial Cells Reveals Stem Cell Characteristics. **In Submission to J Cell Biol.**

Conclusions:

- 1) Fibrogenic cells which reside in fascia and similar tissues in the skeletal muscles contain a population of chondrogenic progenitor cells. Fascia of skeletal muscle could be the tissue from which cells could be harvested for cartilage repair. Future research will focus on isolating these cells and using them to repair cartilage.
- 2) Our study demonstrates that sex influences the chondrogenic differentiation and AC regeneration potential of MDSCs, with M-MDSCs displaying more chondrogenic differentiation and better cartilage regeneration potential than F-MDSCs after cartilage injury.
- 3) sFlt1 gene therapy improved BMP4- and TGF- β 3-induced chondrogenic gene expression of MDSCs *in vitro*, and improved the persistence of repaired articular cartilage by preventing vascularization and bone invasion into the repaired articular cartilage.
- 4) Our results suggest that MDSC-based gene/cell therapy involving sFlt1 and BMP4 repaired articular cartilage after OA mainly by having a beneficial effect on chondrogenesis by the donor and host cells as well as by preventing angiogenesis which eventually prevent cartilage resorption, resulting in a persistent cartilage regeneration and repair.
- 5) Some factor(s) emanating from the synovium are essential for the proper regeneration of OA injured articular cartilage. It could be both the deployment of cells from the synovial tissue that actually participate in the remodeling of the AC and/or the paracrine release of essential factors that aid in the healing process and potentially attract other cell types from the host.
- 6) We have demonstrated that human myoendothelial --a potential human counterpart cell population to the murine MDSCs-- cells possess fundamental properties of stem cells, including self-renewal, clonogenic and multipotent properties (including chondrogenic) *in vitro* and *in vivo*.

Appendices

Appendix 1: Li, GH; Zheng, B; Meszaros, LB; Corsi, KA; Usas, A; Huard, J. Identification and Characterization of Chondrogenic Progenitor Cells in Adult Skeletal Muscle. Orthopaedic Research Society Annual Meeting Feb 2009 (Abstract).

Appendix 2: Matsumoto T, Kubo S, Meszaros L, Corsi K, Cooper G, Li G, Usas A, Osawa A, Fu F, Huard J. The influence of sex on the chondrogenic potential of muscle-derived stem cells. A&R 2008 Dec; 58(12):3809-3819.

Appendix 3: Kubo S, Cooper G, Phillippi J, Corsi K, Usas A, Li G, Freddie F, Huard J. Blocking VEGF with sFlt1 improves the chondrogenic regeneration capacity of skeletal muscle-derived stem cells. A&R 2009 Jan; 60(1):155-165.

Appendix 4: Matsumoto, T ; Cooper, GM; Gharaibeh, B; Meszaros, L; Li G; Usas A; Fu, FH; Huard, J. Cartilage Repair after Osteoarthritis through Intra-articular Injection of Muscle Stem Cells Expressing BMP4 and sFlt1. Orthopaedic Research Society Annual Meeting Feb 2009 (Abstract).

Appendix 5: Matsumoto T, Cooper G, Gharaibeh B, Meszaros L, Li G, Usas A, Fu F, Huard J. Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells

Investigator: Johnny Huard

expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum; Published Online: Apr 29 2009 (p 1390-1405), PMID: 19404941 [PubMed - indexed for MEDLINE].

Identification and Characterization of Chondrogenic Progenitor Cells in Adult Skeletal Muscle

*Li, GH; *Zheng, B; *Meszaros, LB; *Corsi, KA; *Usas, A; +*Huard, J

+*Stem Cell Research Center, Children's Hospital of Pittsburgh of UPMC and Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA
Senior author: jhuard@pitt.edu

INTRODUCTION:

It is observed that fibrogenic cells residing in the fascia (FDCs) in the skeletal muscle are chondrogenic progenitor cells (ORS abstract, 2006, 2007). By definition, the fascia of skeletal muscle is epimysium that covers the entire body of skeletal muscle. In the present study, we hypothesized that cells located in endomysium and perimysium also possess chondrogenic potential (Fig.1). However, physically separating the endomysium and perimysium tissues from skeletal muscle is too difficult to be accomplished. Since endomysium and perimysium tissues are contained in the skeletal muscle, muscle derived cells (MDCs) would contain cells from endomysium and perimysium as well as other populations of cells. The characteristics and chondrogenic differentiation of MDCs were investigated and human FDCs were also examined in the present study.




Fig1. Diagram of skeletal muscle structure

METHODS:

Freshly isolated rat MDCs were analyzed by flow cytometry. They were immunostained by desmin, vimentin and MyoD and their chondrogenic potential was evaluated under the treatment of BMP4 and TGFβ3. Chondrogenic potential of mixed FDCs and rat L6 myoblasts in different ratios (1:0, 4:1, 1:1, 1:4, 0:1 of FDCs to L6 cells) was also investigated. Finally, human FDCs were isolated and characterized, and their chondrogenic potential was also investigated.

RESULTS:

1. MDCs contain FDCs and a population of myogenic cells (Fig.2).
2. MDCs possess strong chondrogenic potential (Fig.2).
3. Chondrogenic assay of mixed FDCs and rat L6 myoblasts in different ratios showed chondrogenic potential is inversely proportional to the percentage of L6 cells (Fig.3).
4. Human FDCs showed more fibrogenic staining and strong chondrogenic potential (Fig.4).




Fig2. (a) Surface marker profile of freshly isolated MDCs. (b) Phenotypic characterization of MDCs. MDCs acquire spindle-shape in vitro. Immunostaining for desmin (red) shows positive cells found in the MDCs. Blue color stains the cells' nuclei. Vimentin (red) staining shows all cells (nuclei, blue) are positive. Myogenic assay shows that myotubes form (arrows). Immunostaining for MyoD (red) shows the positive staining in nuclei of a myotube (arrows). (c) Chondrogenic assay demonstrates positive chondrogenic differentiation of MDCs with safranin O and Alcian blue staining, respectively. (d, e) Under higher

magnification, typical chondrocytes which occupy lacunae within the safranin O positively stained (red) and Alcian blue/ nuclear fast red (blue) cartilage matrix can be observed in the MDCs pellet.




Fig3.(a) With safranin-O and Alcian blue staining, pellets of mixed FDCs and rat myoblast L6 showed decreasing chondrogenic potential with increasing percentage of L6 cells. FDCs display the strongest chondrogenic potential, whereas L6 cells show no chondrogenic differentiation. (b) Quantification of positive area of safranin-O and Alcian blue shows similar results. (c) Under higher magnification, results showed chondrogenic differentiation of FDCs and no chondrogenic differentiation in the L6 group by safranin-O, Alcian blue and collagen II staining.




Fig4. (a) Freshly isolated human FDCs acquire fibroblasts shape in vitro. Immunostaining for desmin (red) shows very few are positive. Vimentin (red) staining shows most of cells (nuclei, blue) are positive. (b,c,d) With safranin-O, Alcian blue and collagen II staining, human FDC pellets show positive staining and typical chondrocytes

DISCUSSION:

Characterization of MDCs demonstrated that they contain at least two populations of cells, FDCs and a population of myogenic cells. Chondrogenic differentiation displayed by muscle derived cells (MDCs) implies that either FDCs, a population of myogenic cells, or both have chondrogenic potential. Mixtures of FDCs and rat L6 myoblasts demonstrated FDCs are the chondrogenic progenitor cell fraction of MDCs, but the myogenic cell fraction of MDCs plays little role in chondrogenesis. Findings about rat FDCs are also supported by the positive chondrogenic differentiation displayed by human FDCs.

In summary, this study shows that fibrogenic cells which reside in fascia and similar tissues in the skeletal muscles contain a population of chondrogenic progenitor cells. Fascia of skeletal muscle could be the tissue from which cells could be harvested for cartilage repair. Future research will focus on isolating these cells and using them to repair cartilage

ACKNOWLEDGMENTS

This work was supported by funding from the Henry J. Mankin Endowed Chair for Orthopaedic Research at the University of Pittsburgh, the William F. and Jean W. Donaldson Chair at Children's Hospital of Pittsburgh, the Hirtzel Foundation, and the National Institutes of Health (R01 AR47973 awarded to J.H.).

Cartilage Repair after Osteoarthritis through Intra-articular Injection of Muscle Stem Cells

Expressing BMP4 and sFlt1

*†† Matsumoto, T; *Cooper, GM; *Gharaibeh, B; *Meszaros, L; *Li G; *Usas A; # Fu, FH; * # Huard, J;

* Stem Cell Research Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh PA. + # Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA. + † Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Senior author jhuard@pitt.edu

Introduction:

Osteoarthritis (OA), a chronic degenerative joint disorder worldwide and characterized by articular cartilage destruction and osteophyte formation, affects over 40 million individuals in the United States alone.

Stem cells are attractive because of their superior capacity for self renewal, proliferation, and survival post-implantation. Several studies have suggested that stem cells can undergo chondrogenesis and repair articular cartilage in experimental cartilage injury models, including studies using muscle derived stem cells (MDSCs). We have already reported that bone morphogenic protein 4 (BMP4) transduced MDSCs improve cartilage regeneration in the *in vitro* pellet culture and the *in vivo* cartilage defect model [1]. The control of angiogenesis such as using sFlt1, vascular endothelial growth factor (VEGF) antagonist, during the chondrogenic differentiation of stem cells is also an important issue to consider especially for the persistence of the regenerate cartilage.

Based on these backgrounds, the series of experiments is designed to clarify the therapeutic efficacy of BMP4 and sFlt1 transduced MDSCs for the repair of articular cartilage after OA.

Methods:

The animal experiments of this study were approved by the Animal Research and Care Committee at Children's Hospital of Pittsburgh.

Isolation of MDSCs: MDSCs were isolated from the hind-limb skeletal muscle of 3-week-old male C57-BL10J mice, via a modified preplate technique that has been previously described [2]. **Retroviral transduction:** MDSCs used were retrovirally transduced with green fluorescence protein (GFP), BMP4-GFP, sFlt1-LacZ, or VEGF-LacZ.

Repair of mono-iodoacetic acid (MIA)-induced arthritis: Transduced MDSCs were injected into the joint capsule 2 weeks after MIA injection (30 nude rats, 60 OA knees). The animals were divided into 5 treatment groups (Table. 1a). **Macroscopic and histological evaluation of cartilage repair:** After macroscopic assessment, we evaluated OA repair semi-quantitatively using a grading and staging system [3]. In this system, there are six histological grades and four histological stages. The total score (score= grade x stage) ranges from 1 point (normal articular cartilage) to 24 points (no repair). **Contribution of transduced MDSCs to cartilage healing:** To histologically assess the contribution of the different types of transduced MDSCs to OA healing in these models, double immunohistochemistry (IHC) for type 2 collagen (Col2) and GFP or β -galactosidase (β -gal) was performed using tissue samples obtained 4 weeks after cell injection. **Chondrocyte apoptosis and proliferation analysis:** To analyze chondrocytes apoptosis and proliferation histologically, TUNEL staining and BrdU incorporation assay was performed using tissue samples obtained 4 weeks after cell infusion (n=6 in each group). **Mixed pellet culture:** To assess the chondrogenic differentiation of MDSCs and their effects on OA chondrocytes, we performed mixed pellet co-culture (Table 1b). Pellets were made in standard chondrogenic medium with 10ng/ml of transforming growth factor-beta3. Pellets were harvested after 14 days in culture and assessed by size, alcian blue staining, quantitative (q) PCR of Col2, Sox9, and Col10, double IHC of Col2 and GFP or β -gal, and fluorescent in situ hybridization (FISH) using mouse Y chromosomes (from the male mouse MDSCs) and rat X chromosomes (from the rat OA chondrocytes). **Separated pellet culture:** To assess the chondrogenesis of OA chondrocytes cultured in the presence of factors released by MDSCs, we performed separated pellet co-culture (Table 1c). Pellets were harvested after 14 days in culture and assessed by size and alcian blue staining.

Results:

Macroscopic and histological evaluation of the joint: *In vivo* testing of articular cartilage regeneration showed macroscopically and histologically that VEGF transduced MDSCs prevented but sFlt1 improved the B4-mediated MDSC regeneration of articular cartilage compared to the B4 alone, as confirmed by histological scores (Fig. 1a).

Contribution of MDSCs in cartilage regeneration and repair: Double IHC of Col2 and GFP or β -gal demonstrated that VEGF transduced MDSCs prevented but sFlt1 improved chondrogenic differentiation of MDSC (Fig. 1b) and intrinsic chondrogenesis (Fig. 1c), compared to BMP4 alone. **Chondrocyte apoptosis and proliferation analyses:** TUNEL stain and BrdU assay demonstrated that sFlt1-transduced MDSCs, unlike VEGF expressing cells, lead to less apoptosis and more proliferation compared to B4 alone (Fig. 1d, e). **Mixed pellet culture:** *In vitro* mixed co-culture showed BMP4 treated group produced significantly larger pellets with hyaline cartilage-like matrix production than all other groups, confirmed by the chondrogenic differentiation capacity of MDSCs using qPCR and qIHC of Col2 and GFP or β -gal. FISH showed no fusion between OA chondrocytes and MDSCs and higher intrinsic chondrogenesis in BMP4 treated group. **Separated pellet culture:** *In vitro* separated co-culture showed BMP4 treated group produced significantly larger pellets with hyaline cartilage-like matrix production than all other groups.


Table 1

a		
Group	Cell type	Cell number (cells)
sFlt1/B4-MDSC	sFlt1-MDSC/BMP4-MDSC	2.5x10 ⁵ /2.5x10 ⁵
VEGF/B4-MDSC	VEGF-MDSC/BMP4-MDSC	2.5x10 ⁵ /2.5x10 ⁵
B4-MDSC	BMP4-MDSC	5.0x10 ⁵
MDSC	MDSCs	5.0x10 ⁵
PBS	No cells	0

b		
Group	Cell type	Cell number (cells)
sFlt1/B4-MDSC+C	sFlt1-MDSC/BMP4-MDSC+OA chondrocyte	0.5x10 ⁵ /0.5x10 ⁵ +1.0x10 ⁶
VEGF/B4-MDSC+C	VEGF-MDSC/BMP4-MDSC+OA chondrocyte	0.5x10 ⁵ /0.5x10 ⁵ +1.0x10 ⁶
B4-MDSC+C	BMP4-MDSC+OA chondrocyte	1.0x10 ⁵ +1.0x10 ⁶
MDSC+C	MDSCs+OA chondrocyte	1.0x10 ⁵ +1.0x10 ⁶
C	OA chondrocyte	2.0x10 ⁶

c		
Group	Cell type (bottom: OA chondrocyte)	Cell number (cells)
sFlt1/B4-MDSC+C	sFlt1-MDSC/BMP4-MDSC+OA chondrocyte	1.0x10 ⁵ /1.0x10 ⁵ +2.0x10 ⁶
VEGF/B4-MDSC+C	VEGF-MDSC/BMP4-MDSC+OA chondrocyte	1.0x10 ⁵ /1.0x10 ⁵ +2.0x10 ⁶
B4-MDSC+C	BMP4-MDSC+OA chondrocyte	2.0x10 ⁵ +2.0x10 ⁶
MDSC+C	MDSCs+OA chondrocyte	2.0x10 ⁵ +2.0x10 ⁶
C	OA chondrocyte	2.0x10 ⁶

Figure 1



Conclusions:

In conclusion, our results suggest that MDSC-based gene/cell therapy involving sFlt1 and BMP4 repaired articular cartilage after OA mainly by having a beneficial effect on chondrogenesis by the donor and host cells as well as by preventing angiogenesis which eventually prevent cartilage resorption, resulting in a persistent cartilage regeneration and repair.

References:

- [1] Kuroda R, et al. *Arthritis Rheum.* 2006;54(2):433-42.
- [2] Qu Z, et al. *J Cell Biol.* 2002; 27;157(5):851-64.

Cartilage Repair in a Rat Model of Osteoarthritis Through Intraarticular Transplantation of Muscle-Derived Stem Cells Expressing Bone Morphogenetic Protein 4 and Soluble Flt-1

Tomoyuki Matsumoto,¹ Gregory M. Cooper,¹ Burhan Gharaibeh,¹ Laura B. Meszaros,¹ Guangheng Li,² Arvydas Usas,² Freddie H. Fu,³ and Johnny Huard¹

Objective. The control of angiogenesis during chondrogenic differentiation is an important issue affecting the use of stem cells in cartilage repair, especially with regard to the persistence of regenerated cartilage. This study was undertaken to investigate the effect of vascular endothelial growth factor (VEGF) stimulation and the blocking of VEGF with its antagonist, soluble Flt-1 (sFlt-1), on the chondrogenesis of skeletal muscle-derived stem cells (MDSCs) in a rat model of osteoarthritis (OA).

Methods. We investigated the effect of VEGF on cartilage repair in an immunodeficiency rat model of OA after intraarticular injection of murine MDSCs expressing bone morphogenetic protein 4 (BMP-4) in combination with MDSCs expressing VEGF or sFlt-1.

Results. In vivo, a combination of sFlt-1- and BMP-4-transduced MDSCs demonstrated better repair without osteophyte formation macroscopically and histologically following OA induction, when compared with the other groups. Higher differentiation/proliferation

and lower levels of chondrocyte apoptosis were also observed in sFlt-1- and BMP-4-transduced MDSCs compared with a combination of VEGF- and BMP-4-transduced MDSCs or with BMP-4-transduced MDSCs alone. In vitro experiments with mixed pellet coculture of MDSCs and OA chondrocytes revealed that BMP-4-transduced MDSCs produced the largest pellets, which had the highest gene expression of not only type II collagen and SOX9 but also type X collagen, suggesting formation of hypertrophic chondrocytes.

Conclusion. Our results demonstrate that MDSC-based therapy involving sFlt-1 and BMP-4 repairs articular cartilage in OA mainly by having a beneficial effect on chondrogenesis by the donor and host cells as well as by preventing angiogenesis, which eventually prevents cartilage resorption, resulting in persistent cartilage regeneration and repair.

Osteoarthritis (OA), a chronic degenerative joint disorder with worldwide impact, is characterized by articular cartilage destruction and osteophyte formation. OA affects >40 million individuals in the US alone and influences more lives than any other musculoskeletal condition (1). Since articular cartilage is a tissue type that is poorly supplied by blood vessels, nerves, and the lymphatic system, it has a very limited capacity for repair after injury. Although several therapies have been used for OA, no widely accepted treatments have been established, with the exception of arthroplasty. For this reason, tissue engineering techniques aimed at repairing articular cartilage have been extensively studied, and chondrocyte transplantation has already been performed (2–4).

Currently, the most effective treatment for OA, besides arthroplasty, is autologous chondrocyte transplantation. However, this treatment has several limitations, including the need to use neighboring healthy

Supported by the US Department of Defense (contract W81XWH-08-0076). Dr. Huard's work was supported by the William F. and Jean W. Donaldson Chair at the Children's Hospital of Pittsburgh, and the Henry J. Mankin Endowed Chair for Orthopaedic Research at the University of Pittsburgh.

¹Tomoyuki Matsumoto, MD, PhD, Gregory M. Cooper, PhD, Burhan Gharaibeh, PhD, Laura B. Meszaros, BS, Johnny Huard, PhD: Children's Hospital of Pittsburgh, and University of Pittsburgh, Pittsburgh, Pennsylvania; ²Guangheng Li, MD, PhD, Arvydas Usas, MD: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; ³Freddie H. Fu, MD: University of Pittsburgh, Pittsburgh, Pennsylvania.

Dr. Huard has received consulting fees from Cook Myosite, Inc. (more than \$10,000) and receives royalties from Cook Myosite, Inc. for the licensing through the University of Pittsburgh of patented technology for the preplate technique for isolation of muscle-derived stem cells.

Address correspondence and reprint requests to Johnny Huard, PhD, Stem Cell Research Center, Children's Hospital of Pittsburgh, 4100 Rangos Research Center, 3705 Fifth Avenue, Pittsburgh, PA 15213-2582. E-mail: jhuard@pitt.edu.

Submitted for publication September 3, 2008; accepted in revised form January 19, 2009.

donor cartilage, difficulty in treating large-scale defects, limited expansion capacity of primary chondrocytes, and the need for a periosteal patch to maintain engineered cartilage. In addition, in most cases only 30–40% of the defect regenerates articular cartilage, with the remaining defect being filled with fibrocartilage (5,6).

In light of these limitations, it is important to find other sources of cells that are abundant and capable of chondrogenic differentiation. Muscle stem cells are more attractive than primary chondrocytes because of their superior capacity for self-renewal, proliferation, and survival following environmental stress (7–9). Recently, stem cell-based therapies have been used clinically for cartilage repair (10,11). The results of several previous studies, including those using muscle-derived stem cells (MDSCs), have indicated that stem cells can undergo chondrogenesis and repair articular cartilage in experimental cartilage injury models (12–15). We previously demonstrated that bone morphogenetic protein 4 (BMP-4)-transduced MDSCs improved cartilage formation in an in vitro pellet culture and regeneration in an in vivo cartilage defect model (13). Based on those results, the present study was designed to clarify the therapeutic efficacy of BMP-4-transduced MDSCs in OA.

The control of angiogenesis during chondrogenic differentiation is one of the most important issues affecting the application of stem cells for cartilage repair. Among angiogenesis-modulating factors, including antiangiogenic factors such as troponin 1 (16) and chondromodulin 1 (17), vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis (18). VEGF stimulates capillary formation in vivo and exerts direct mitogenic actions on various cells in vitro (19). In the growth plate, VEGF has been reported to play an essential role in cartilage vascularization and absorption of hypertrophic chondrocytes, which together lead to ossification (20,21). Similar to this endochondral ossification, osteophyte formation during OA development has been reported to involve VEGF signaling (22).

Similarly, recent data reveal the expression of VEGF and its receptors (Flt-1 and Flk-1) in OA cartilage and reflect the ability of VEGF to enhance catabolic pathways in chondrocytes by stimulating matrix metalloproteinase (MMP) activity and reducing tissue inhibitors of MMPs (TIMPs) (23–25). These data suggest that, apart from the effect of VEGF on cartilage vascularization and proliferation of cells in the synovial membrane, chondrocyte-derived VEGF promotes catabolic pathways in the cartilage itself, thereby leading to a progressive breakdown of the extracellular matrix (ECM) of articular cartilage.

In the current study, we used a gain- and loss-of-function approach based on tissue engineering techniques to assess the role of VEGF in MDSC-mediated cartilage repair. We demonstrated that genetically modified MDSCs expressing a VEGF antagonist and BMP-4 and transplanted intracapsularly in a rat model of OA enhanced chondrogenesis, repaired cartilage via the autocrine/paracrine effects of BMP-4, and contributed to an appropriate environment that prevented chondrocyte apoptosis by blocking both the intrinsic VEGF catabolic pathway and extrinsic VEGF-induced vascular invasion. This is the first report to describe the effects of VEGF on MDSC-mediated chondrogenesis and OA repair in vitro and in vivo.

MATERIALS AND METHODS

Isolation of MDSCs. MDSCs were isolated from the hind limb skeletal muscle of 3-week-old male C57BL/10J mice (The Jackson Laboratory, Bar Harbor, ME) via a previously described modified preplate technique (7).

Retroviral transduction. Retroviral vectors encoding for green fluorescent protein (GFP), BMP-4 and GFP (BMP-4-GFP), human VEGF₁₆₅ and bacterial nuclear-localized LacZ (VEGF-LacZ), or human soluble Flt-1 (sFlt-1), a VEGF antagonist, and LacZ (sFlt-1-LacZ) expression were generated as previously described (26). Transduction efficiency was ~80% for each retroviral vector. MDSCs were transduced separately with these retroviral vectors at a multiplicity of infection of 5 in the presence of 8 μ g/ml of Polybrene. The transduced cells were expanded for 2 weeks before being used in experiments, and the conditioned media were sampled to determine transgene expression. The level of BMP-4 secreted from the transduced cells was estimated with a BMP-4 bioassay, as previously described (27). The levels of VEGF or sFlt-1 secreted by the transduced cells were confirmed by enzyme-linked immunosorbent assay (ELISA) as previously described (28).

Repair of mono-iodoacetate (MIA)-induced arthritis. The animal experiments conducted as a part of this study were approved by the Animal Research and Care Committee at Children's Hospital of Pittsburgh. Sixty 10-week-old female nude rats (NIH-*Wm* NIH-RNU-M; Taconic, Germantown, NY) were used. The animals were anesthetized with 3% isoflurane and O₂ gas (1.5 liters/minute) delivered through an inhalation mask. OA-like arthritis was induced by a single intraarticular injection of MIA (Aldrich Chemical, Milwaukee, WI) (0.3 mg per 150 mg body weight) into both knee joints of the rats.

Rats were divided into 2 groups based on OA model ($n = 30$ rats [60 knees] per group) and further divided into 5 groups based on treatment type ($n = 6$ rats [12 knees] per group). The 2 models of OA were a chronic disease model in which rats were intraarticularly injected with cells after OA had progressed significantly (2 weeks after MIA injection) and a subacute disease model in which rats were treated with cells before significant OA progression (1 week after MIA injection). Rats in treatment group 1 received 2.5×10^5 sFlt-1-transduced MDSCs combined with 2.5×10^5 BMP-4-transduced MDSCs in phosphate buffered saline (PBS) (sFlt-

1/BMP-4-MDSC group). Group 2 rats were treated with 2.5×10^5 VEGF-transduced MDSCs combined with 2.5×10^5 BMP-4-transduced MDSCs in PBS (VEGF/BMP-4-MDSC group). Group 3 rats were treated with 5.0×10^5 BMP-4-transduced MDSCs in PBS (BMP-4-MDSC group). Group 4 rats were treated with 5×10^5 MDSCs in PBS (MDSC group), and group 5 rats were treated with PBS alone (PBS group). Rats were allowed to move freely within their cages after cell injection. Rats were killed 4 weeks (both chronic OA and subacute OA models), 12 weeks (chronic OA model), or 16 weeks (subacute OA model) after cell transplantation ($n = 6$ OA knees for each time point).

Tissue harvest. After macroscopic examination, 6 distal femora per group per time point were dissected for histologic and histochemical staining and fixed with 10% neutral buffered formalin for 48 hours, followed by decalcification with 10% EDTA for 2 weeks and paraffin embedding. For immunohistochemical staining, 6 distal femora per group at week 4 were harvested and quickly embedded in OCT compound (Miles, Elkhart, IN), snap-frozen in liquid nitrogen, and stored at -80°C until used.

Histologic evaluation of cartilage repair. Sagittal sections ($5 \mu\text{m}$ thick) were obtained and stained with Safranin O-fast green. We evaluated OA repair semiquantitatively using a grading and staging system (29). This system included 6 histologic grades and 4 histologic stages. The total score (grade multiplied by stage) ranged from 1 point (normal articular cartilage) to 24 points (no repair).

Contribution of transduced MDSCs to cartilage healing. Rat femurs in OCT-embedded blocks were sectioned, and $5\text{-}\mu\text{m}$ serial sections were mounted on silane-coated glass slides and air dried for 1 hour before being fixed with 4.0% paraformaldehyde at 4°C for 5 minutes and stained immediately. To detect transplanted mouse cells in the articular cartilage of the femoral condyle, immunohistochemistry was performed at week 4 (in 6 additional rats in each group) with the following antibodies: rabbit anti-rat type II collagen (Col2) (Sigma, St. Louis, MO) to detect rat and mouse chondrocytes (mouse via cross-reactivity of the antibody with mouse Col2 [13]), Alexa Fluor 488-conjugated rabbit anti-GFP (Molecular Probes, Eugene, OR) for detection of BMP-4 and GFP-transduced MDSCs and GFP-transduced MDSCs, and biotin-conjugated anti- β -galactosidase (anti- β -gal) for detection of sFlt-1 and LacZ-transduced MDSCs and VEGF and LacZ-transduced MDSCs.

GFP or LacZ genes were used to distinguish the contributions of BMP-4-transduced MDSCs from those of nontransduced MDSCs and of sFlt-1-transduced MDSCs from those of VEGF-transduced MDSCs. In addition, due to green autofluorescence in GFP, red fluorescence was applied for LacZ staining to avoid false-positive staining. Double immunohistochemistry with GFP or β -gal and Col2 was performed to detect the contribution of transduced MDSCs to cartilage healing. To assess the contribution of intracapsular-injected MDSCs, the number of double-positive or Col2-positive cells was morphometrically counted as the average value in 5 randomly selected articular cartilage areas in the femoral condyle. The following secondary antibodies were used for each immunostaining: Cy3-conjugated or fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (Molecular Probes) for Col2 staining, and Cy3-conjugated streptavidin (Molecular Probes) for β -gal staining. For nuclear staining,

4',6-diamidino-2-phenylindole (DAPI) solution was applied for 5 minutes.

Analysis of chondrocyte apoptosis and proliferation. Sagittal paraffin-embedded sections ($5 \mu\text{m}$ thick) were obtained, and the TUNEL assay was performed at week 4 using an Apop Tag Plus Peroxidase In Situ Apoptosis Detection kit according to the recommendations of the manufacturer (Chemicon, Temecula, CA). Briefly, sections were incubated with $15 \mu\text{g/ml}$ of proteinase K for 15 minutes at room temperature, and then washed in PBS. Endogenous peroxidase was quenched with 3% H_2O_2 for 5 minutes at room temperature. After washing in PBS, sections were immersed in buffer containing terminal deoxynucleotidyl transferase enzyme and incubated for 90 minutes at 37°C in a humid atmosphere. After washing again in PBS, sections were incubated with antidigoxigenin conjugate for 30 minutes at room temperature. After washing in PBS and developing color in peroxidase substrate with diaminobenzidine, signals were examined by microscopy ($n = 6$ rats from each treatment group).

To measure cell proliferation, immunohistochemistry was performed, using additional animals at week 4, on formalin-fixed, bromodeoxyuridine (BrdU)-incorporated, paraffin-embedded sections, as previously described (20). BrdU was administered intraperitoneally to rats, at 50 mg/kg , 1 and 24 hours before the rats were killed in order to incorporate enough BrdU. After a 20-minute treatment with 0.05% trypsin at 37°C and a 45-minute treatment with 95% formamide in 0.15M trisodium citrate at 70°C for denaturing, tissues were stained overnight at 4°C with mouse biotin-conjugated anti-BrdU (Zymed, San Diego, CA) at a dilution of 1:1,000. Signals were then detected using the Vectastain ABC Standard Elite kit (Vector, Burlingame, CA) ($n = 6$ rats from each treatment group). Labeled nuclei were counted in 5 independent, randomly selected fields.

Isolation of rat OA chondrocytes and normal mouse chondrocytes. Articular cartilage was removed from the femoral condyles of rats 2 weeks after injection of MIA under sterile conditions. The tissue fragments were cut into 1-mm slices and washed 4 times with PBS containing 100 units/ml of penicillin and $100 \mu\text{g/ml}$ of streptomycin. Slices were cut into small pieces and incubated for 16–24 hours with 1.5 mg/ml of collagenase B (Roche, Mannheim, Germany) and 1 mM cysteine in Dulbecco's modified Eagle's medium (DMEM). The cell suspension was filtered through a $20\text{-}\mu\text{m}$ nylon mesh to remove debris and washed 3 times with calcium-free DMEM. The cells were seeded at a density of $100,000 \text{ cells/cm}^2$ overnight at 37°C in a humidified atmosphere containing 5% CO_2 and used for each experiment. Similarly, normal mouse chondrocytes were isolated from mouse articular cartilage and used as controls.

Mixed pellet culture. Pellet culture was performed as described previously (30). Mixed pellet cultures consisted of the following: 1) 0.5×10^5 sFlt-1-transduced MDSCs, 0.5×10^5 BMP-4-transduced MDSCs, and 1.0×10^5 OA chondrocytes (sFlt-1/BMP-4-MDSC plus chondrocytes group), 2) 0.5×10^5 VEGF-transduced MDSCs, 0.5×10^5 BMP-4-transduced MDSCs, and 1.0×10^5 OA chondrocytes (VEGF/BMP-4-MDSC plus chondrocytes group), 3) 1.0×10^5 BMP-4-transduced MDSCs and 1.0×10^5 OA chondrocytes (BMP-4-MDSC plus chondrocytes group), 4) 1.0×10^5 nontransduced MDSCs and 1.0×10^5 OA chondrocytes (MDSC plus chondrocytes group), and 5) 2.0×10^5 OA chondrocytes

(chondrocytes group). Pellets were made in 0.5 ml of chondrogenic medium that contained DMEM supplemented with 1% penicillin/streptomycin, $10^{-7}M$ dexamethasone, 50 $\mu g/ml$ of ascorbate 2-phosphate, 40 $\mu g/ml$ of proline, 100 $\mu g/ml$ of pyruvate, and 1% BD ITS+ (insulin–transferrin–selenium) premix (Becton Dickinson, Franklin Lakes, NJ) with 10 ng/ml of transforming growth factor $\beta 3$ (R&D Systems, Minneapolis, MN). The pellets were incubated at 37°C in 5% CO_2 , and the medium was changed every 2 to 3 days. Pellets were harvested after 14 days in culture.

Separated pellet culture. MDSCs and OA chondrocytes were separated by sterilized culture plate insert (Millicell; Millipore, Bedford, MA). Pellets of OA chondrocytes were made in the medium at the bottom of a 15-ml tube, as previously described (31). The membrane plate was inserted into the 15-ml tube so that the MDSC pellets were placed within the membrane plate. Separated pellets were made with 1) 1.0×10^5 sFlt-1-transduced MDSCs, 1.0×10^5 BMP-4-transduced MDSCs, and 2.0×10^5 OA chondrocytes (sFlt-1/BMP-4–MDSC plus chondrocytes group), 2) 1.0×10^5 VEGF-transduced MDSCs, 1.0×10^5 BMP-4-transduced MDSCs, and 2.0×10^5 OA chondrocytes (VEGF/BMP-4–MDSC plus chondrocytes group), 3) 2.0×10^5 BMP-4-transduced MDSCs and 2.0×10^5 OA chondrocytes (BMP-4–MDSC plus chondrocytes group), 4) 2.0×10^5 nontransduced MDSCs and 2.0×10^5 OA chondrocytes (MDSC plus chondrocytes group), and 5) 2.0×10^5 OA chondrocytes (chondrocytes group). Pellets were made in 0.5 ml of chondrogenic medium. The pellets were incubated at 37°C in 5% CO_2 , and the medium was changed every 2–3 days. Pellets were harvested after 14 days in culture.

ELISA assessment of VEGF levels. VEGF levels in the medium were measured 48 hours after pellet culture in both mixed pellet culture and pellet coculture using an ELISA kit according to the recommendations of the manufacturer (R&D Systems) ($n = 3$ in each group).

Alcian blue staining. Paraffin sections of the pellets were deparaffinized, placed in 3% acetic acid for 3 minutes, and transferred into Alcian blue solution (pH 2.5) for 30 minutes. The slides were rinsed with running tap water for 10 minutes and counterstained with nuclear fast red.

Differentiation of MDSCs into chondrocytes. Pellets in OCT blocks were sectioned and prepared for staining as described above. To detect mouse cells in the pellets, double immunohistochemistry ($n = 3$) was performed as described above. To assess the contribution of each MDSC, the number of double-positive cells and Col2-positive cells was determined in 5 randomly selected soft tissue fields in the pellets, and the average value was calculated.

Quantitative real-time reverse transcriptase-polymerase chain reaction (PCR) analysis of pellet cultured cells. Messenger RNA was isolated using the RNeasy Plus kit, according to the recommendations of the manufacturer (Qiagen, Valencia, CA). After RNA extraction, quantitative PCR analysis of pellets was carried out as described previously (32). Gene expression levels were calculated based on the ΔC_t method. All target genes were normalized to the housekeeping gene *18S*; *18S* primers and probes were designed by and purchased from Applied Biosystems (Foster City, CA). Primers and probes were designed for Col2, SOX9, and type X collagen (Col10) according to GenBank sequence. All target gene primers and probes were purchased from Integrated

DNA Technologies (Coralville, IA). For quantitative PCR assays, the coefficients of variation calculated from triplicate assays were within 3%.

The following primer sequences and probes were used: for mouse Col2, forward AAG-TCA-CTG-AAC-AAC-CAG-ATT-GAG-A, reverse AAG-TGC-GAG-CAG-GGT-TCT-TG, and TaqMan probe ATC-CGC-AGC-CCC-GAC-GGC-T; for mouse SOX9, forward CGG-CTC-CAG-CAA-GAA-CAA-G, reverse TGC-GCC-CAC-ACC-ATG-A, and TaqMan probe ACG-TCA-AGC-GAC-CCA-TGA-ACG-C; and for mouse Col10, forward TAC-TTA-CAC-GGA-TGG-AGA-CCA-TGT-T, reverse ATC-CAG-TTG-ACT-ACT-GGT-GCA-ATT-T, and TaqMan probe AAC-CCT-CTT-TTC-GGA-TTA-ACC-CTG-CGA-GTT.

Fluorescence in situ hybridization (FISH). Slides from frozen sections were fixed with 4% paraformaldehyde, air dried, and then dehydrated in a series of successive concentrations of 70%, 80%, 95%, and 100% ethanol for 3 minutes each. Slides were incubated in pepsin solution for 5 minutes, then washed in 2 $\times$ sodium chloride–sodium citrate (SSC), and dehydrated. FITC-conjugated mouse Y chromosome probe and rhodamine-conjugated rat X chromosome were mixed with hybridization buffer according to the recommendations of the manufacturer (ID Labs Biotechnology, London, Ontario, Canada) and were applied to the target area on the slide, covered with a coverslip, and sealed with rubber cement. After the cement had dried (~10 minutes at room temperature), the slides and probe were codenatured by placing on a heating block (Fisher, Kalamazoo, MI) set at 68.5°C for 5 minutes followed by hybridization overnight in a prewarmed, opaque humidified chamber at 37°C. On day 2, the rubber cement and coverslips were removed by soaking briefly in 2 $\times$ SSC solution (pH 7.0) at 45°C. Excess probe was rinsed with 50% formamide–2 $\times$ SSC for 12 minutes; followed by 20 minutes in 2 $\times$ SSC at 45°C. Nuclei were counterstained with DAPI.

Statistical analysis. All values are expressed as the mean $\pm$ SEM. Paired *t*-tests were performed for comparison of data before and after treatment. The comparisons among the 5 groups were made using one-way analysis of variance. Post hoc analysis was performed using Fisher's protected least significant difference test. Histologic scores were compared using the Kruskal-Wallis test. *P* values less than 0.05 were considered significant.

RESULTS

Macroscopic and histologic findings in the joints.

Transduced MDSCs were injected into the joint capsule 2 weeks after MIA injection ($n = 30$ rats [60 OA knees]). The animals were divided into 5 treatment groups (sFlt-1/BMP-4–MDSC, VEGF/BMP-4–MDSC, BMP-4–MDSC, nontransduced MDSC, and PBS groups). MDSCs used were retrovirally transduced with GFP, BMP-4–GFP, sFlt-1–LacZ, or VEGF–LacZ. There was no gross evidence of any side effects such as infection or tumor formation throughout the observation period.

Four weeks after MDSC transplantation into the OA model (2 weeks of induction), macroscopic evaluation of the sFlt-1/BMP-4-transduced MDSC group re-




Figure 1. A and B, Macroscopic (A) and histologic (B) evaluation of representative joints from rats injected with muscle-derived stem cells (MDSCs) transduced with soluble Flt-1 (sFlt-1) and bone morphogenetic protein 4 (BMP-4 [B4]) (sFlt-1/BMP-4-MDSC), MDSCs transduced with vascular endothelial growth factor (VEGF) and BMP-4 (VEGF/BMP-4-MDSC), MDSCs transduced with BMP-4 alone (BMP-4-MDSC), nontransduced MDSCs (MDSC), or phosphate buffered saline (PBS) alone, 4 and 12 weeks after transplantation. Four weeks after transplantation, the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups macroscopically and histologically showed smooth joint surface with well-repaired articular cartilage and Safranin O-positive hyaline-like cartilage (red staining in B). However, the other groups showed marked arthritic progression, synovial hypertrophy, and osteophyte formation (arrows). Twelve weeks after transplantation, although the sFlt-1/BMP-4-MDSC group still showed well-repaired articular cartilage, the other groups exhibited more severe arthritis compared with 4 weeks. (Original magnification $\times 100$.) C, Semiquantitative histologic scores for all groups, 4 and 12 weeks following transplantation. The sFlt-1/BMP-4-MDSC group had the lowest (best) scores of all groups. Bars show the mean and SEM. ** = $P < 0.05$ versus all other groups; * = $P < 0.05$ versus the VEGF/BMP-4-MDSC, MDSC, and PBS groups.

vealed smooth joint surfaces of articular cartilage and no osteophyte formation (Figure 1A). Although the BMP-4-transduced MDSC group also showed well-healed articular surfaces, some parts of the joints included osteophyte formation (Figure 1A). However, the VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups showed marked arthritis including synovial hypertrophy and osteophyte formation (Figure 1A).

Histologic assessment demonstrated that Safranin O-positive hyaline-like cartilage was present in the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups only, and the BMP-4-MDSC group had much less Safranin O staining than did the sFlt-1/BMP-4-MDSC group (Figure 1B). However, Safranin O-positive hyaline-like cartilage was less prominent in the nontransduced MDSC group and was completely absent in both the VEGF/BMP-4-MDSC and PBS groups (Figure 1B).

Twelve weeks after transplantation, rat knees treated with sFlt-1/BMP-4-MDSCs still showed smooth joint surfaces in most regions of the articular condyles (Figure 1A). In the BMP-4-MDSC group, although the articular cartilage surfaces tended to be smooth, osteophyte formation was more advanced than at 4 weeks (Figure 1A). The VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups showed marked progression of arthritis (Figure 1A). Histologic assessment also demonstrated that more Safranin O-positive tissue and fewer clusters of chondrocytes near necrotic tissue were found in the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups compared with the other groups (Figure 1B). Destructive events, including pannus invasion, osteolysis, cyst formation within the subchondral bone area, and cartilage tissue lacking Safranin O-positive staining were observed in the VEGF/BMP-4-MDSC and PBS groups (Figure 1B).




Figure 2. Contribution of MDSCs to cartilage regeneration and repair. **A**, Double immunohistochemical staining for type II collagen (Col2) and green fluorescent protein (GFP). The sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups showed significantly higher levels of chondrogenic differentiation than did the other groups. **B**, Double immunohistochemical staining for Col2 and β -galactosidase (β -gal). The sFlt-1/BMP-4-MDSC group showed higher levels of chondrogenic differentiation than did the VEGF/BMP-4-MDSC group. In **A** and **B**, the last panel shows a higher-magnification view of the boxed area in the first panel. **Arrows** show double-positive cells. Bars = 20 μ m. **C**, Numbers of GFP-positive and β -gal-positive cells in each group. The total chondrogenic differentiation of MDSCs was significantly greater in the sFlt-1/BMP-4-MDSC group than in the other groups. Bars show the mean and SEM. * = $P < 0.05$ versus the VEGF/BMP-4-MDSC and MDSC groups; †† = $P < 0.05$ versus all other groups; † = $P < 0.05$ versus the VEGF/BMP-4-MDSC, MDSC, and PBS groups; # = $P < 0.05$ versus the VEGF/BMP-4-MDSC group. **D**, Total number of Col2-positive cells in each group. The sFlt-1/BMP-4-MDSC group had a significantly greater number of chondrocytes than did the other groups. Bars show the mean and SEM. ** = $P < 0.05$ versus all other groups; * = $P < 0.05$ versus the VEGF/BMP-4-MDSC, MDSC, and PBS groups. See Figure 1 for other definitions.

A previously described histologic grading scale (28) was used to evaluate the quality of the repaired tissue. Four weeks after transplantation, the total score in the sFlt-1/BMP-4-MDSC group was significantly lower than that in all of the other groups. The score in the BMP-4-MDSC group was significantly lower than the scores in the VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups (mean $\pm$ SEM score 4.7 ± 0.8 in sFlt-1/BMP-4-MDSC, 18.7 ± 1.3 in VEGF/BMP-4-MDSC, 10.0 ± 1.3 in BMP-4-MDSC, 12.3 ± 1.3 in nontransduced MDSC, and 17.3 ± 0.8 in the PBS group) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups, and for BMP-4-MDSC versus VEGF/BMP-4-MDSC and PBS groups; $P < 0.05$ for sFlt-1/BMP-4-MDSC versus BMP-4-MDSC group, and for BMP-4-MDSC versus nontransduced MDSC group) (Figure 1C).

Twelve weeks after transplantation, the total score in the sFlt-1/BMP-4-MDSC group was also significantly lower than that in all other groups. The score in the BMP-4-MDSC group was significantly lower than the scores in the VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups (mean $\pm$ SEM score 4.3 ± 0.8 in sFlt-1/BMP-4-MDSC, 20.7 ± 1.3 in VEGF/BMP-4-MDSC, 11.5 ± 0.5 in BMP-4-MDSC, 14.7 ± 0.8 in nontransduced MDSC, and 19.3 ± 1.3 in the PBS group) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus VEGF/BMP-4-MDSC, nontransduced MDSC, and PBS groups, and for BMP-4-MDSC versus VEGF/BMP-4-MDSC and PBS groups; $P < 0.05$ for sFlt-1/BMP-4-MDSC versus BMP-4-MDSC group, and for BMP-4-MDSC versus nontransduced MDSC group) (Figure 1C). Notably, although the scores in the sFlt-1/BMP-4-MDSC group at 12 weeks were similar to the scores at the 4-week time




Figure 3. Chondrocyte apoptosis and proliferation. **A**, TUNEL staining in all groups 4 weeks after transplantation. The sFlt-1/BMP-4-MDSC group had significantly fewer apoptotic cells, and the VEGF/BMP-4-MDSC group had a greater number of apoptotic cells, compared with the other groups. **B**, Bromodeoxyuridine (BrdU) assay in all groups 4 weeks after transplantation. The sFlt-1/BMP-4-MDSC group had a significantly greater number of proliferative cells, and the VEGF/BMP-4-MDSC group had fewer proliferative cells, compared with the other groups. In **A** and **B**, the last panel shows a higher-magnification view of the boxed area in the first panel. Bars = 50 μ m. **C**, Number of TUNEL-positive cells in each group. **D**, Number of BrdU-positive cells in each group. Bars in **C** and **D** show the mean and SEM. ** = $P < 0.05$ versus all other groups; * = $P < 0.05$ versus the VEGF/BMP-4-MDSC, MDSC, and PBS groups. See Figure 1 for other definitions.

point, all other treatment groups showed variable levels of disease progression.

Contribution of MDSCs to cartilage regeneration and repair. To histologically assess the contribution of the different types of transduced MDSCs to OA healing in these models, double immunohistochemical staining for Col2 and GFP or β -gal was performed using tissue samples obtained 4 weeks after cell injection. Differentiated chondrocytes derived from transduced MDSCs were detected in the superficial and mid-zones of the articular cartilage of the femoral condyle, by double-positive staining for Col2 and either GFP or β -gal, depending on the cell type used. All cells that were transduced to express BMP-4 were also transduced to express GFP. Also, the control MDSCs used for the MDSC group were transduced to express GFP. GFP-positive cells expressing Col2 were found in the femoral condyles in all groups except the PBS control group, which received no GFP-labeled MDSCs (Figure 2A). Cells that were transduced to express VEGF or sFlt-1

were also transduced to express β -gal using the LacZ gene. Within the knee, cells that coexpressed Col2 and β -gal were identified (Figure 2B).

Quantification of the number of cells that were double positive for Col2 and GFP demonstrated that the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups showed significantly higher numbers of GFP-labeled cells differentiated into Col2-expressing cells (chondrocytes) compared with the VEGF/BMP-4-MDSC and nontransduced MDSC groups (mean $\pm$ SEM cells/mm² 58.7 $\pm$ 7.9 in sFlt-1/BMP-4-MDSC, 18.7 $\pm$ 4.9 in VEGF/BMP-4-MDSC, 56.0 $\pm$ 5.5 in BMP-4-MDSC, and 26.7 $\pm$ 5.3 in MDSC) ($P < 0.01$ for sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups versus VEGF/BMP-4-MDSC and nontransduced MDSC groups) (Figure 2C).

Colocalization of Col2 and β -gal demonstrated that the sFlt-1/BMP-4-MDSC group had significantly more β -gal-positive chondrocytes than did the VEGF/BMP-4-MDSC group (mean $\pm$ SEM cells/mm² 29.3 $\pm$ 6.4 in sFlt-1/BMP-4-MDSC and 10.7 $\pm$ 3.4 in VEGF/

BMP-4-MDSC) ($P < 0.01$) (Figure 2C). Total counts of cells that were double positive for Col2 and either GFP or β -gal indicated that the sFlt-1/BMP-4-MDSC group contained significantly more double-positive cells than did the BMP-4-MDSC, VEGF/BMP-4-MDSC, and nontransduced MDSC groups (mean $\pm$ SEM cells/mm² 88.0 $\pm$ 3.6 in sFlt-1/BMP-4-MDSC, 29.3 $\pm$ 4.9 in VEGF/BMP-4-MDSC, 56.0 $\pm$ 5.5 in BMP-4-MDSC, and 26.7 $\pm$ 5.3 in nontransduced MDSC) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus BMP-4-MDSC, VEGF/BMP-4-MDSC, and MDSC groups, and for BMP-4-MDSC versus VEGF/BMP-4-MDSC and MDSC groups) (Figure 2C).

The total number of Col2-positive cells (chondrocytes from MDSCs and host chondrocytes) was also significantly higher in the sFlt-1/BMP-4-MDSC group than in the other groups (mean $\pm$ SEM cells/mm² 173.3 $\pm$ 12.0 in sFlt-1/BMP-4-MDSC, 37.3 $\pm$ 3.4 in VEGF/BMP-4-MDSC, 117.3 $\pm$ 8.9 in BMP-4-MDSC, 64.0 $\pm$ 8.3 in MDSC, and 29.3 $\pm$ 2.7 in the PBS group) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus all other groups; $P < 0.05$ for BMP-4-MDSC versus VEGF/BMP-4-MDSC, MDSC, and PBS groups) (Figure 2D).

Results of chondrocyte apoptosis and proliferation analyses. To analyze chondrocyte apoptosis histologically, TUNEL staining was performed using tissue samples obtained 4 weeks after cell infusion. Chondrocyte apoptosis was less abundant in the superficial and mid-zones of the articular cartilage of the femoral condyle, especially in the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups compared with the VEGF/BMP-4-MDSC group (Figure 3A). Quantification of TUNEL staining showed that the sFlt-1/BMP-4-MDSC group had significantly fewer apoptotic chondrocytes compared with other treatment groups (mean $\pm$ SEM cells/mm² 46.5 $\pm$ 7.1 in sFlt-1/BMP-4-MDSC, 268.5 $\pm$ 30.2 in VEGF/BMP-4-MDSC, 99.0 $\pm$ 7.3 in BMP-4-MDSC, 138.0 $\pm$ 11.3 in MDSC, and 190.5 $\pm$ 15.3 in the PBS group) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus VEGF/BMP-4-MDSC, MDSC, and PBS groups, and for BMP-4-MDSC versus VEGF/BMP-4-MDSC and PBS groups; $P < 0.05$ for sFlt-1/BMP-4-MDSC versus BMP-4-MDSC, and for BMP-4-MDSC versus MDSC) (Figure 3C).

A BrdU incorporation assay was performed on tissue samples from 4-week postoperative animals in order to assess cell proliferation in the knee joint. Proliferating cells were identified primarily in the superficial and mid-zones of the femoral articular cartilage, especially in the sFlt-1/BMP-4-MDSC and BMP-4-MDSC groups (Figure 3B). The number of BrdU-positive chondrocytes was significantly higher in the

sFlt-1/BMP-4-MDSC group compared with all other groups (mean $\pm$ SEM cells/mm² 207.0 $\pm$ 16.1 in sFlt-1/BMP-4-MDSC, 16.2 $\pm$ 3.4 in VEGF/BMP-4-MDSC, 122.4 $\pm$ 11.9 in BMP-4-MDSC, 61.2 $\pm$ 11.5 in MDSC, and 19.8 $\pm$ 1.8 in the PBS group) ($P < 0.01$ for sFlt-1/BMP-4-MDSC versus all other groups, and for BMP-4-MDSC versus VEGF/BMP-4-MDSC and PBS groups; $P < 0.05$ for BMP-4-MDSC versus MDSC) (Figure 3D).

Results of mixed pellet culture. To assess the chondrogenic differentiation of MDSCs and their effects on OA chondrocytes, we performed mixed-cell micro-mass pellet culture (Figure 4A). ELISA for VEGF levels in the control medium of unmixed pellet culture and in mixed pellet culture showed that VEGF action in MDSCs was blocked by sFlt-1 and significantly enhanced by BMP-4 (mean $\pm$ SEM pg/ml per 48 hours 426.7 $\pm$ 8.8 in sFlt-1/BMP-4-MDSC plus chondrocytes, 872.0 $\pm$ 5.7 in VEGF/BMP-4-MDSC plus chondrocytes, 759.2 $\pm$ 15.5 in BMP-4-MDSC plus chondrocytes, 724.9 $\pm$ 4.0 in MDSC plus chondrocytes, 270.4 $\pm$ 14.8 in chondrocytes alone, 524.9 $\pm$ 4.0 in MDSC, 84.3 $\pm$ 29.1 in sFlt-1-MDSC, 806.2 $\pm$ 7.6 in VEGF-MDSC, and 637.6 $\pm$ 19.7 in BMP-4-MDSC) ($P < 0.01$ for all paired comparisons except for BMP-4-MDSC plus chondrocytes versus MDSC plus chondrocytes) (Figure 4B).

Pellets formed using BMP-4-MDSCs and OA chondrocytes were significantly larger than the pellets formed with the other cell types. Also, the pellets formed by mixing cells expressing sFlt-1 were larger than the other mixed-cell combinations, with the exception of the BMP-4-MDSC plus chondrocytes group (mean $\pm$ SEM mm 1.40 $\pm$ 0.05 in sFlt-1/BMP-4-MDSC plus chondrocytes, 1.13 $\pm$ 0.05 in VEGF/BMP-4-MDSC plus chondrocytes, 1.62 $\pm$ 0.07 in BMP-4-MDSC plus chondrocytes, 1.22 $\pm$ 0.09 in MDSC plus chondrocytes, and 0.93 $\pm$ 0.06 in chondrocytes alone) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes, MDSC plus chondrocytes, and chondrocytes alone, and for sFlt-1/BMP-4-MDSC plus chondrocytes versus chondrocytes alone; $P < 0.05$ for BMP-4-MDSC plus chondrocytes versus sFlt-1/BMP-4-MDSC plus chondrocytes, and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes) (Figure 4C).

All of the pellets from every group showed hyaline cartilage-like ECM that stained positively for Alcian blue and contained well-differentiated, round chondrocyte-like cells (Figure 4D). Double immunohistochemical staining for Col2 and either GFP or β -gal showed that chondrocyte-like cells within the pellets




Figure 4. A, Mixed pellet coculture of MDSCs and osteoarthritic (OA) chondrocytes. B, Levels of VEGF in the medium of mixed pellet coculture in each group. VEGF activity in MDSCs was blocked by sFlt-1 and enhanced by BMP-4. Bars show the mean and SEM. C, Size of pellets in mixed pellet coculture in each group. The BMP-4-MDSC plus chondrocytes group formed significantly larger pellets compared with the other groups. Bars show the mean and SEM. * = $P < 0.05$ versus the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups; ** = $P < 0.05$ versus all other groups. D, Alcian blue staining in each group. C = OA chondrocytes. E, Double immunohistochemical staining for type II collagen (Col2) and green fluorescent protein (GFP). The BMP-4-MDSC plus chondrocytes group formed a significantly greater number of chondrocytes than did the sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes groups. F, Double immunohistochemical staining for Col2 and β -galactosidase (β -gal). The sFlt-1/BMP-4-MDSC plus chondrocytes group formed a significantly greater number of chondrocytes than did the VEGF/BMP-4-MDSC plus chondrocytes group. Arrows show double-positive cells. Bars = 20 μ m. G, Numbers of GFP-positive and β -gal-positive cells in each group. Bars show the mean and SEM. ** = $P < 0.05$ versus all other groups; * and # = $P < 0.05$ versus the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups. See Figure 1 for other definitions.

were derived from BMP-4/GFP-MDSCs and GFP-MDSCs in the sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes groups (Figure 4E) and from the sFlt-1/LacZ-MDSCs and VEGF/LacZ-MDSCs in the sFlt-1/BMP-4-MDSC plus chondrocytes and VEGF/BMP-4-MDSC plus chondrocytes groups (Figure 4F).

The number of double-positive cells was significantly higher in the BMP-4-MDSC plus chondrocytes group compared with sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes groups (mean $\pm$ SEM 133.3 $\pm$

16.7 in sFlt-1/BMP-4-MDSC plus chondrocytes, 41.7 $\pm$ 8.3 in VEGF/BMP-4-MDSC plus chondrocytes, 208.3 $\pm$ 16.7 in BMP-4-MDSC plus chondrocytes, 33.3 $\pm$ 8.3 in MDSC plus chondrocytes) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus all other groups; sFlt-1/BMP-4-MDSC versus VEGF/BMP-4-MDSC and MDSC groups) (Figure 4G).

Double staining for Col2 and β -gal demonstrated that the number of double-positive cells was significantly higher in the sFlt-1/BMP-4-MDSC plus chondrocytes group compared with the VEGF/BMP-4-MDSC plus chondrocytes group (mean $\pm$ SEM mm² 66.7 $\pm$ 8.3 in sFlt-1/BMP-4-MDSC plus chondrocytes and 33.3 $\pm$ 8.3




Figure 5. Quantitative polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) analysis. **A**, Gene expression of type II collagen (Col2), SOX9, and type X collagen (Col10) in each group, as assessed by quantitative PCR analysis. Pellets from the BMP-4-MDSC plus osteoarthritic (OA) chondrocytes group showed significantly higher gene expression of Col2 and SOX9 than did the other groups; the sFlt-1/BMP-4-MDSC plus chondrocytes group had higher Col2 and SOX9 expression than did the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups. Pellets from the BMP-4-MDSC plus chondrocytes group showed significantly higher gene expression of Col10 than did the other groups; the MDSC plus chondrocytes group had higher Col10 expression than did the sFlt-1/BMP-4-MDSC plus chondrocytes and VEGF/BMP-4-MDSC plus chondrocytes groups. Bars show the mean and SEM. **, ##, and †† = $P < 0.05$ versus all other groups; *, #, and † = $P < 0.05$ versus the sFlt-1/BMP-4-MDSC plus chondrocytes and VEGF/BMP-4-MDSC plus chondrocytes groups. **B–G**, FISH analysis of mixed pellets of normal rat chondrocytes (**B**), mouse MDSCs (**C**), sFlt-1/BMP-4-MDSC plus chondrocytes (**D**), VEGF/BMP-4-MDSC plus chondrocytes (**E**), BMP-4-MDSC plus chondrocytes (**F**), and MDSC plus chondrocytes (**G**), demonstrating that chondrogenic differentiation of mouse MDSCs did not occur through cell fusion (complex of rat X chromosome [red] and mouse Y chromosome [green]). Bars = 20 μ m. **H**, Quantification of chondrocytes derived from mouse MDSCs and of rat chondrocytes in each group. The sFlt-1/BMP-4-MDSC plus chondrocytes (**C**) and BMP-4-MDSC plus chondrocytes groups formed significantly more rat chondrocytes and mouse MDSC-derived chondrocytes than did the other groups. The total number of chondrocytes was significantly higher in the BMP-4-MDSC plus chondrocytes group. Bars show the mean and SEM. * and # = $P < 0.05$ versus the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups; †† = $P < 0.05$ versus all other groups; † = $P < 0.05$ versus the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups. See Figure 1 for other definitions.

in VEGF/BMP-4-MDSC plus chondrocytes) ($P < 0.05$) (Figure 4G).

Quantitative PCR and FISH. Quantitative PCR analysis demonstrated that pellets from the BMP-4-MDSC plus chondrocytes group showed significantly higher gene expression of Col2 than did the sFlt-1/BMP-

4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes groups; Col2 gene expression in the sFlt-1/BMP-4-MDSC plus chondrocytes group was higher than that in the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups (mean $\pm$ SEM 0.063 $\pm$

0.0087 in sFlt-1/BMP-4-MDSC plus chondrocytes, 0.022 ± 0.0018 in VEGF/BMP-4-MDSC plus chondrocytes, 0.091 ± 0.0058 in BMP-4-MDSC plus chondrocytes, 0.020 ± 0.0051 in MDSC plus chondrocytes, 0.154 ± 0.0090 in chondrocytes alone, 0.041 ± 0.0020 in MDSC, 0.057 ± 0.012 in sFlt-1-MDSC, 0.011 ± 0.00030 in VEGF-MDSC, and 0.069 ± 0.0043 in BMP-4-MDSC ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes, and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes) (Figure 5A).

Pellets from the BMP-4-MDSC plus chondrocytes group showed significantly higher gene expression of SOX9 than did those from the sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes groups; SOX9 gene expression was higher in the sFlt-1/BMP-4-MDSC plus chondrocytes group than in the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups (mean $\pm$ SEM 0.0064 ± 0.00044 in sFlt-1/BMP-4-MDSC plus chondrocytes, 0.0010 ± 0.00019 in VEGF/BMP-4-MDSC plus chondrocytes, 0.015 ± 0.0021 in BMP-4-MDSC plus chondrocytes, 0.0031 ± 0.0030 in MDSC plus chondrocytes, 0.033 ± 0.0070 in chondrocytes alone, 0.0043 ± 0.0018 in MDSC, 0.0033 ± 0.0021 in sFlt-1-MDSC, 0.0011 ± 0.00014 in VEGF-MDSC, and 0.0092 ± 0.0034 in BMP-4-MDSC) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes; $P < 0.01$ for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes) (Figure 5A).

Additionally, pellets from the BMP-4-MDSC plus chondrocytes group showed significantly higher gene expression of Col10 than did those from the other groups; Col10 gene expression was higher in the MDSC plus chondrocytes group than in the sFlt-1/BMP-4-MDSC plus chondrocytes and VEGF/BMP-4-MDSC plus chondrocytes groups (mean $\pm$ SEM 0.000022 ± 0.0000031 in sFlt-1/BMP-4-MDSC plus chondrocytes, 0.000023 ± 0.0000036 in VEGF/BMP-4-MDSC plus chondrocytes, 0.000056 ± 0.0000056 in BMP-4-MDSC plus chondrocytes, 0.000034 ± 0.000011 in MDSC plus chondrocytes, 0.000026 ± 0.0000072 in chondrocytes alone, 0.000031 ± 0.0000049 in MDSC, 0.000016 ± 0.0000072 in sFlt-1-MDSC, 0.000012 ± 0.0000022 in VEGF-MDSC, and 0.000045 ± 0.0000057 in BMP-4-MDSC) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus sFlt-1/BMP-4-MDSC plus chondrocytes, VEGF/

BMP-4-MDSC plus chondrocytes, and MDSC plus chondrocytes, and for MDSC plus chondrocytes versus sFlt-1/BMP-4-MDSC plus chondrocytes and VEGF/BMP-4-MDSC plus chondrocytes) (Figure 5A).

To determine whether the chondrogenic differentiation of MDSCs occurred through fusion of MDSCs with chondrocytes or through direct differentiation of the MDSCs, we performed FISH with mouse Y chromosomes (from male mouse MDSCs) and rat X chromosomes (from rat OA chondrocytes). The specificity of the probes was tested in pellets of normal rat chondrocytes (Figure 5B) and mouse MDSCs (Figure 5C). The FISH analysis revealed no nuclei in which the mouse Y chromosome colocalized with the rat X chromosome (Figures 5D–G), suggesting that cellular fusion between MDSCs and OA chondrocytes was unlikely in this experiment (Figures 5D–G).

The FISH analysis also demonstrated that the number of MDSCs was significantly higher in the sFlt-1/BMP-4-MDSC plus chondrocytes (Figure 5D) and BMP-4-MDSC plus chondrocytes groups (Figure 5F) than in the VEGF/BMP-4-MDSC plus chondrocytes (Figure 5E) and MDSC plus chondrocytes groups (Figure 5G) (mean $\pm$ SEM number/mm² 182.7 ± 6.8 in sFlt-1/BMP-4-MDSC plus chondrocytes, 78.7 ± 8.7 in VEGF/BMP-4-MDSC plus chondrocytes, 217.3 ± 9.0 in BMP-4-MDSC plus chondrocytes, and 118.0 ± 7.6 in MDSC plus chondrocytes) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus all other groups and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups) (Figure 5H).

Notably, the number of rat chondrocytes was also significantly higher in the sFlt-1/BMP-4-MDSC plus chondrocytes and BMP-4-MDSC plus chondrocytes groups than in the VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups (mean $\pm$ SEM number/mm² 158.7 ± 16.7 in sFlt-1/BMP-4-MDSC plus chondrocytes, 66.0 ± 4.2 in VEGF/BMP-4-MDSC plus chondrocytes, 218.0 ± 12.1 in BMP-4-MDSC plus chondrocytes, and 115.3 ± 5.9 in MDSC plus chondrocytes) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus all other groups, and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups) (Figure 5H).

The total number of rat chondrocytes and MDSCs was significantly higher in the BMP-4-MDSC plus chondrocytes group than in all other groups (mean $\pm$ SEM number/mm² 341.3 ± 23.5 in sFlt-1/BMP-4-MDSC plus chondrocytes, 144.7 ± 4.7 in VEGF/BMP-4-MDSC plus chondrocytes, 435.3 ± 19.8




Figure 6. A, Separated pellet coculture of MDSCs and osteoarthritic (OA) chondrocytes. B, Size of pellets in each group. OA chondrocytes in the BMP-4-MDSC plus chondrocytes group formed significantly larger pellets compared with the other groups. Bars show the mean and SEM. ** = $P < 0.05$ versus all other groups; * = $P < 0.05$ versus the VEGF/BMP-4-MDSC plus chondrocytes, MDSC plus chondrocytes, and chondrocytes alone groups. C, Alcian blue staining in each group. C = OA chondrocytes (see Figure 1 for other definitions).

in BMP-4-MDSC plus chondrocytes, and 233.3 ± 10.3 in MDSC plus chondrocytes) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus all other groups and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes and MDSC plus chondrocytes groups) (Figure 5H).

Results of separated pellet culture. To assess the chondrogenesis of OA chondrocytes cultured in the presence of factors released by MDSCs, we performed micromass pellet coculture (Figure 6A). Pellet size analysis showed that OA chondrocytes cocultured with BMP-4-MDSCs formed significantly larger pellets compared with all other groups (mean $\pm$ SEM mm 1.39 ± 0.04 in sFlt-1/BMP-4-MDSC plus chondrocytes, 1.12 ± 0.07 in VEGF/BMP-4-MDSC plus chondrocytes, 1.65 ± 0.04 in BMP-4-MDSC plus chondrocytes, 1.16 ± 0.03 in MDSC plus chondrocytes, and 1.09 ± 0.07 in chondrocytes alone) ($P < 0.01$ for BMP-4-MDSC plus chondrocytes versus all other groups, and for sFlt-1/BMP-4-MDSC plus chondrocytes versus VEGF/BMP-4-MDSC plus chondrocytes, MDSC plus chondrocytes, and chondrocytes alone) (Figure 6B). All of the pellets from every group showed hyaline cartilage-like ECM that

stained positively for Alcian blue and contained well-differentiated, round chondrocytic cells (Figure 6C).

DISCUSSION

Researchers use different rat models of OA to confirm the effectiveness of different treatments. OA-like arthritis is primarily induced by surgical procedures or chemical adjuvants, such as MIA (32–36). Surgically induced OA models may be more clinically relevant than chemically induced models with regard to the pathophysiology of OA. However, there are several drawbacks to surgically induced OA models, including the need for surgical manipulation to induce OA and the difficulty in achieving reproducible levels of severity of arthritis. Therefore, we used an MIA-induced OA model and confirmed the reproducibility of the grade and stage of OA in immunodeficient rats, which was consistent with previous reports of OA in other rat strains (32–34) (Additional information is available upon request from the corresponding author.)

Our in vivo macroscopic and histologic evaluations showed that sFlt-1/BMP-4-transduced MDSCs

had the greatest potential for cartilage repair in the chemically induced OA model. In contrast, the mixture of BMP-4-expressing cells and VEGF-expressing cells led to marked arthritis progression, including synovial hypertrophy, pannus invasion, and osteophyte formation (Figure 1). In a previous study, we found that BMP-4-transduced MDSCs had a higher potential for cartilage regeneration and repair than did nontransduced MDSCs in an osteochondral defect model in the nude rat (13). In the gain- and loss-of-function experiments conducted in the present study, we demonstrated that sFlt-1 improved, and VEGF delayed, cartilage repair with BMP-4-transduced MDSCs in the chemically induced OA model.

Interestingly, in the model of subacute OA the regenerative effects in the sFlt-1/BMP-4-MDSC group were observed up to 16 weeks. (Results in the subacute group are available upon request from the corresponding author.) This same treatment was less effective at the same time in the model in which OA was induced for 2 weeks (chronic OA model). These findings suggest that, to obtain long-term beneficial results, a combined treatment consisting of sFlt-1 (antiangiogenic factor) and BMP-4 with MDSCs is more beneficial in subacute OA than in chronic OA.

In the present study, even when transplanted within the joint space (intraarticularly), MDSCs were found to undergo chondrogenic differentiation, as evidenced by double-positive staining for the GFP or β -gal transgenes and the chondrocyte marker Col2. This showed that both chondrogenic differentiation of transduced MDSCs and intrinsic chondrogenesis were most frequently found in the sFlt-1/BMP-4-treated group, although similar results were found in the BMP-4-transduced MDSC group (Figure 2). In a previous study, we demonstrated that BMP-4 secretion by transduced MDSCs influences the differentiation of multipotent MDSCs toward the chondrogenic lineage *in vitro* and *in vivo* (13). Additionally, the present study showed that sFlt-1 improved, while VEGF inhibited, the chondrogenic differentiation of these BMP-4-transduced MDSCs in an OA model.

Furthermore, the intrinsic chondrogenic potential of BMP-4-transduced MDSCs was found to be higher than that of nontransduced MDSCs both *in vitro* and *in vivo*. In this study, sFlt-1 enhanced the chondrogenic potential of BMP-4-expressing cells, while VEGF reduced this potential (Figure 2). We reason that the *in vivo* results that were observed were due to an improvement in chondrogenic differentiation of both the host OA chondrocytes and the implanted MDSCs through the activity of BMP-4, and due to the prevention of

vascularization and bone invasion into the regenerated cartilage tissue through the activity of sFlt-1 (23,25).

To attempt to better delineate the mechanism behind the beneficial effects of sFlt-1 and BMP-4 treatment, we performed apoptosis and proliferation assays *in vivo* (Figure 3). TUNEL assay (apoptosis) results suggested that VEGF induced higher levels of chondrocyte apoptosis and reduced levels of cellular proliferation in the OA knee. In contrast, sFlt-1-treated OA knees showed the lowest level of chondrocyte apoptosis and the highest level of cell proliferation. There are 2 plausible mechanisms by which VEGF may affect cartilage degeneration in OA. VEGF may directly increase catabolic pathways in cartilage tissue through the stimulation of MMP activity and the reduction of TIMPs (23,25). Additionally, VEGF may indirectly cause cartilage destruction by enhancing angiogenesis and vascular invasion, leading to replacement of cartilage by bone. Although the *in vivo* results presented here support the assertion that VEGF is detrimental to cartilage, we decided to examine whether VEGF worked directly or indirectly on the OA-derived chondrocytes.

In an attempt to establish conditions similar to those in the *in vivo* experiment, we used *in vitro* mixed and separated coculture systems to investigate the interaction between transduced MDSCs and OA-derived chondrocytes. The mixed-cell pellet culture showed that, although sFlt-1-transduced and VEGF-transduced MDSCs themselves did not alter chondrogenic potential in an autocrine manner, secreted sFlt-1 enhanced, and VEGF prevented, the chondrogenic differentiation of BMP-4-transduced MDSCs in a paracrine manner. However, BMP-4-transduced MDSCs formed the largest pellets and showed the highest rate of differentiation into chondrocytes (Figure 4). These results indicate that blocking and enhancing VEGF may partially affect the chondrogenic differentiation of BMP-4-transduced MDSCs *in vitro*, but that BMP-4 itself plays an important role in enhancing the chondrogenic differentiation of MDSCs in an autocrine/paracrine manner, as previously described by our group (13).

In addition, quantitative PCR analysis demonstrated that BMP-4-transduced MDSCs (double dose compared with sFlt-1/BMP-4-MDSCs and VEGF/BMP-4-MDSCs) showed higher gene expression not only of Col2 and SOX9 but also of Col10 (Figure 5A), suggesting that the higher dose of BMP-4 caused differentiation toward hypertrophic chondrocytes. These findings may indicate that a high dose of BMP-4 leads to overproliferation of chondrocytes. In this assay, however, ELISA showed up-regulated VEGF secretion of MDSCs by BMP-4 (Figure 4).

In another previous study, we showed that the beneficial effect of VEGF on bone healing elicited by BMP-4 depended critically on the ratio of VEGF to BMP-4, with an improper ratio leading to detrimental effects on bone healing (26). These findings may indicate that VEGF in moderate concentrations, as opposed to overexpression, maintains chondrocyte survival and control cell differentiation and proliferation *in vitro*, as previously described (20,37–39). The results of the mixed pellet coculture system indicate that sFlt-1 and BMP-4-expressing MDSCs offer the best balanced combination therapy, despite the fact that the largest pellets in BMP-4-expressing MDSCs also contained the highest gene expression of Col10 (Figures 4 and 5A).

We also tested the separated cell coculture system to investigate the intrinsic effects of sFlt-1, VEGF, and BMP-4 secreted from transduced MDSCs on OA chondrocytes. The results suggest that BMP-4 secreted by MDSCs produced the largest pellets, whereas sFlt-1 enhanced, and VEGF inhibited, the chondrogenic potential of OA chondrocytes to various degrees (Figure 6). These results suggest that BMP-4 mainly affects the redifferentiation or proliferation of OA chondrocytes *in vitro*. These *in vitro* mixed and separated pellet coculture experiments suggest the following mechanism: BMP-transduced MDSCs act through an autocrine/paracrine system by releasing BMP-4 that affects the MDSCs themselves, nearby MDSCs, and nearby OA chondrocytes, up-regulating chondrogenesis *in vitro*. In contrast, VEGF and sFlt-1 secreted by MDSCs have little effect on the chondrogenic differentiation of MDSCs themselves. However, both VEGF and sFlt-1 have some effects on the chondrogenic differentiation of BMP-4-transduced MDSCs and nearby OA chondrocytes.

Stem cells have been reported to undergo multilineage differentiation, but this capacity has recently been a subject of controversy because of possible fusion of stem cells with target-differentiated/lineage-committed cells in the target tissue (39,40). Following these first reports, many researchers reported differentiation of stem cells through fusion with target mature cells, such as hepatocytes with hematopoietic stem cells (41,42), cardiomyocytes with hematopoietic/endothelial progenitor cells (43,44), and neural cells with neural stem cells (45,46). Whether MDSCs undergo chondrogenic differentiation through fusion needed to be addressed.

In addition to characterizing the autocrine/paracrine effect of MDSCs, the present study investigated whether fusion of MDSCs and OA chondrocytes occurred during chondrogenic differentiation. FISH ana-

lysis using mixed-cell pellet culture of MDSCs and OA chondrocytes demonstrated no chondrocytes in which the mouse Y chromosome (from the MDSCs) was colocalized with rat X chromosome (from rat OA chondrocytes) (Figures 5B–G), suggesting that there was a lack of fusion between the 2 different cell types. These findings suggest that MDSCs adopted the chondrocyte-like phenotype through potential differentiation without fusion with previously existing chondrocytes. However, the Y chromosome probe is not 100% efficient. This inefficiency may have resulted in an underestimation of the numbers of mouse cells and the possibility that some cell fusion events may have occurred, but were not detected.

In addition, FISH analysis demonstrated the contribution of mouse MDSCs and rat OA chondrocytes. Quantification of the nuclei from cells surrounded by Alcian blue-positive tissue (Figure 4) demonstrated that the total contribution of MDSCs and OA chondrocytes was significantly greater in the BMP-4-MDSC group than in the sFlt-1/BMP-4-MDSC group, consistent with the larger pellet size in the groups that included BMP-4-expressing cells. Taken together, these findings indicate that sFlt-1 may enhance, and VEGF may inhibit, the chondrogenic differentiation of BMP-4-transduced MDSCs and the proliferation of OA chondrocytes; however, these effects are significantly lower than the potential of BMP-4-transduced MDSCs *in vitro*.

The results of this study support the published data that suggest that VEGF triggers cartilage destruction (23,25,47,48), since we observed that the addition of VEGF inhibited cartilage repair and regeneration or accelerated degeneration in the *in vivo* OA model. Also, the best histologically assessed regeneration of cartilage *in vivo* was found in knees treated with both MDSCs expressing BMP-4 and MDSCs expressing sFlt-1, when VEGF signaling was blocked. However, our *in vitro* results from mixed and separated cell pellet cultures, which were designed to simulate the *in vivo* situation, showed that the BMP-4-MDSC group had the greatest chondrogenic potential, rather than the sFlt-1/BMP-4-MDSC group. These results suggest that sFlt-1 has more of an enhancing effect *in vivo*.

With cell markers and flow cytometry, investigators at our laboratory have recently identified and purified a distinct cell population that is developmentally and anatomically related to blood vessels or blood vessel walls within human tissue (49,50). The myoendothelial cells are found in skeletal muscle and coexpress markers of endothelial and myogenic cells (CD34 and CD56) (50). The pericytes are found in multiple human organs including skeletal muscle, pancreas, adipose tis-

sue, and placenta and are isolated based on CD146, nerve/glia antigen 2, and platelet-derived growth factor receptor β expression and absence of hematopoietic, endothelial, and myogenic cell markers (49). These cell populations exhibit multilineage differentiation potential and can, in culture and in vivo, differentiate into myogenic, osteogenic, chondrogenic, and adipogenic cells. In the near future, based on the present findings, we should confirm the potential of this human cell population for cartilage healing and repair in OA.

In conclusion, sFlt-1/BMP-4-transduced MDSCs, VEGF-blocking treatment, which were transplanted intraarticularly in a rat model of OA, enhanced chondrogenesis and chondrogenic regeneration via the autocrine/paracrine effects of BMP-4, and contributed to an appropriate environment that prevented chondrocyte apoptosis by blocking the intrinsic VEGF catabolic pathway and extrinsic VEGF-induced vascular invasion. Blocking VEGF, combined with BMP-4 treatment, of MDSCs is a potentially effective therapy for OA repair that may improve the quality and persistence of regenerated articular cartilage.

ACKNOWLEDGMENTS

The authors are grateful to Jessica Tebbets and Michele Keller for excellent technical help.

AUTHOR CONTRIBUTIONS

Dr. Huard had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study design. Matsumoto, Cooper, Li, Huard.

Acquisition of data. Matsumoto, Gharaibeh, Li, Usas.

Analysis and interpretation of data. Cooper, Gharaibeh, Meszaros, Li, Usas, Fu, Huard.

Manuscript preparation. Matsumoto, Cooper, Gharaibeh, Meszaros, Li, Usas, Fu, Huard.

Statistical analysis. Cooper, Meszaros.

Study oversight and direction. Fu, Huard.

REFERENCES

- Buckwalter JA, Stanish WD, Rosier RN, Schenck RC Jr, Dennis DA, Coutts RD. The increasing need for nonoperative treatment of patients with osteoarthritis. *Clin Orthop Relat Res* 2001;36–45.
- Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 1994;331:889–95.
- Ochi M, Uchio Y, Kawasaki K, Wakitani S, Iwasa J. Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee. *J Bone Joint Surg Br* 2002;84:571–8.
- Visna P, Pasa L, Cizmar I, Hart R, Hoch J. Treatment of deep cartilage defects of the knee using autologous chondrograft transplantation and by abrasive techniques—a randomized controlled study. *Acta Chir Belg* 2004;104:709–14.
- O'Driscoll SW. The healing and regeneration of articular cartilage. *J Bone Joint Surg Am* 1998;80:1795–812.
- Bentley G, Biant LC, Carrington RW, Akmal M, Goldberg A, Williams AM, et al. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. *J Bone Joint Surg Br* 2003;85:223–30.
- Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 2002;157:851–64.
- Deasy BM, Gharaibeh BM, Pollett JB, Jones MM, Lucas MA, Kanda Y, et al. Long-term self-renewal of postnatal muscle-derived stem cells. *Mol Biol Cell* 2005;16:3323–33.
- Oshima H, Payne TR, Urish KL, Sakai T, Ling Y, Gharaibeh B, et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. *Mol Ther* 2005;12:1130–41.
- Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. *Cell Transplant* 2004;13:595–600.
- Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage* 2007;15:226–31.
- Adachi N, Sato K, Usas A, Fu FH, Ochi M, Han CW, et al. Muscle derived, cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects. *J Rheumatol* 2002;29:1920–30.
- Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. *Arthritis Rheum* 2006;54:433–42.
- Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1994;76:579–92.
- Koga H, Muneta T, Ju YJ, Nagase T, Nimura A, Mochizuki T, et al. Synovial stem cells are regionally specified according to local microenvironments after implantation for cartilage regeneration. *Stem Cells* 2007;25:689–96.
- Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, et al. Troponin I is present in human cartilage and inhibits angiogenesis. *Proc Natl Acad Sci U S A* 1999;96:2645–50.
- Shukunami C, Oshima Y, Hiraki Y. Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. *Biochem Biophys Res Commun* 2005;333:299–307.
- Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. *J Cell Sci* 2001;114(Pt 5):853–65.
- Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. *J Biol Chem* 1996;271:603–6.
- Maes C, Stockmans I, Moermans K, van Looveren R, Smets N, Carmeliet P, et al. Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. *J Clin Invest* 2004;113:188–99.
- Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nat Med* 1999;5:623–8.
- Hashimoto S, Creighton-Achermann L, Takahashi K, Amiel D, Coutts RD, Lotz M. Development and regulation of osteophyte formation during experimental osteoarthritis. *Osteoarthritis Cartilage* 2002;10:180–7.
- Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. *J Pathol* 2004;202:367–74.
- Pfander D, Kortje D, Zimmermann R, Weseloh G, Kirsch T,

- Gesslein M, et al. Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. *Ann Rheum Dis* 2001;60:1070-3.
25. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, et al. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. *Am J Pathol* 2003;162:171-81.
 26. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J Clin Invest* 2002;110:751-9.
 27. Peng H, Chen ST, Wergedal JE, Polo JM, Yee JK, Lau KH, et al. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. *Mol Ther* 2001;4:95-104.
 28. Peng H, Usas A, Olshanski A, Ho AM, Gearhart B, Cooper GM, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage* 2006;14:13-29.
 29. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage* 2006;14:13-29.
 30. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* 1998;238:265-72.
 31. Jadowiec J, Koch H, Zhang X, Campbell PG, Seyedain M, Sfeir C. Phosphorylation regulates the gene expression and differentiation of NIH3T3, MC3T3-E1, and human mesenchymal stem cells via the integrin/MAPK signaling pathway. *J Biol Chem* 2004;279:53323-30.
 32. Van der Kraan PM, Vitters EL, van de Putte LB, van den Berg WB. Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints. *Am J Pathol* 1989;135:1001-14.
 33. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. *Arthritis Rheum* 1997;40:1670-9.
 34. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. *Osteoarthritis Cartilage* 2001;9:751-60.
 35. Stoop R, Buma P, van der Kraan PM, Hollander AP, Billingham RC, Meijers TH, et al. Type II collagen degradation in articular cartilage fibrillation after anterior cruciate ligament transection in rats. *Osteoarthritis Cartilage* 2001;9:308-15.
 36. Janusz MJ, Bendele AM, Brown KK, Taiwo YO, Hsieh L, Heitmeyer SA. Induction of osteoarthritis in the rat by surgical tear of the meniscus: inhibition of joint damage by a matrix metalloproteinase inhibitor. *Osteoarthritis Cartilage* 2002;10:785-91.
 37. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. *Development* 2004;131:2161-71.
 38. Zelzer E, Olsen BR. Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. *Curr Top Dev Biol* 2005;65:169-87.
 39. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* 2002;416:542-5.
 40. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. *Nature* 2002;416:545-8.
 41. Camargo FD, Finegold M, Goodell MA. Hematopoietic myelomonocytic cells are the major source of hepatocyte fusion partners. *J Clin Invest* 2004;113:1266-70.
 42. Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S, et al. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. *Nat Med* 2004;10:744-8.
 43. Zhang S, Wang D, Estrov Z, Raj S, Willerson JT, Yeh ET. Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. *Circulation* 2004;110:3803-7.
 44. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. *Nat Med* 2004;10:494-501.
 45. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. *Nature* 2003;425:968-73.
 46. Chen KA, Laywell ED, Marshall G, Walton N, Zheng T, Steindler DA. Fusion of neural stem cells in culture. *Exp Neurol* 2006;198:129-35.
 47. Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. *Arthritis Rheum* 1998;41:1632-8.
 48. Tanaka E, Aoyama J, Miyauchi M, Takata T, Hanaoka K, Iwabe T, et al. Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. *Histochem Cell Biol* 2005;123:275-81.
 49. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 2008;3:301-13.
 50. Zheng B, Cao B, Crisan M, Sun B, Li G, Logar A, et al. Prospective identification of myogenic endothelial cells in human skeletal muscle. *Nat Biotechnol* 2007;25:1025-34.

The Influence of Sex on the Chondrogenic Potential of Muscle-Derived Stem Cells

Implications for Cartilage Regeneration and Repair

Tomoyuki Matsumoto,¹ Seiji Kubo,¹ Laura B. Meszaros,² Karin A. Corsi,² Gregory M. Cooper,² Guangheng Li,² Arvydas Usas,² Aki Osawa,¹ Freddie H. Fu,³ and Johnny Huard¹

Objective. To explore possible differences in muscle-derived stem cell (MDSC) chondrogenic differentiation in vitro and articular cartilage regeneration in vivo between murine male MDSCs (M-MDSCs) and female MDSCs (F-MDSCs).

Methods. Three different populations of M- and F-MDSCs (n = 3 of each sex) obtained via preplate technique, which separates cells based on their variable adhesion characteristics, were compared for their in vitro chondrogenic potential using pellet culture. Cells were assayed with and without retroviral transduction to express bone morphogenetic protein 4 (BMP-4). The influence of both expression of stem cell marker Sca1 and in vitro expansion on the chondrogenic potential of M- and F-MDSCs was also determined. Additionally, BMP-4–transduced M- and F-MDSCs were applied to a full-thickness articular cartilage defect (n = 5 each) on the femur of a nude rat, and the quality of the repaired

tissue was evaluated by macroscopic and histologic examination.

Results. With and without BMP-4 gene transduction, M-MDSCs produced significantly larger pellets with a richer extracellular matrix, compared with F-MDSCs. Sca1 purification influenced the chondrogenic potential of MDSCs, especially M-MDSCs. Long-term culture did not affect the chondrogenic potential of M-MDSCs but did influence F-MDSCs. M-MDSCs repaired articular cartilage defects more effectively than did F-MDSCs at all time points tested, as assessed both macroscopically and histologically.

Conclusion. Our findings demonstrate that sex influences the chondrogenic differentiation and articular cartilage regeneration potential of MDSCs. Compared with female MDSCs, male MDSCs display more chondrogenic differentiation and better cartilage regeneration potential.

Supported by the US Department of Defense (contract W81XWH-08-0076), the William F. and Jean W. Donaldson Chair at the Children's Hospital of Pittsburgh (Dr. Huard), and the Henry J. Mankin Endowed Chair in Orthopaedic Surgery at the University of Pittsburgh (Dr. Huard).

¹Tomoyuki Matsumoto, MD, PhD, Seiji Kubo, MD, Aki Osawa, MD, PhD, Johnny Huard, PhD: Children's Hospital of Pittsburgh and University of Pittsburgh, Pittsburgh, Pennsylvania; ²Laura B. Meszaros, BS, Karin A. Corsi, PhD, Gregory M. Cooper, PhD, Guangheng Li, MD, PhD, Arvydas Usas, MD: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; ³Freddie H. Fu, MD: University of Pittsburgh, Pittsburgh, Pennsylvania.

Drs. Matsumoto and Kubo contributed equally to this work.

Dr. Huard has received consulting fees from Cook MyoSite, Inc. (more than \$10,000).

Address correspondence and reprint requests to Johnny Huard, PhD, Children's Hospital of Pittsburgh, 4100 Rangos Research Center, 3705 Fifth Avenue, Pittsburgh, PA 15213-2582. E-mail: jhuard@pitt.edu.

Submitted for publication June 13, 2008; accepted in revised form August 29, 2008.

Articular cartilage damage is difficult to treat because the tissue lacks a blood, nerve, and lymph supply and has limited intrinsic capacity to repair. Injury-related full-thickness articular cartilage defects or large defects caused by osteoarthritis (OA) may require substantial surgical treatments, including bone stimulation techniques (multiple perforations, abrasions, and microfractures) in which subchondral bone is broken to facilitate repair of cartilage damage caused by bone marrow–derived cells and cytokines. However, these methods result in the presence of fibrocartilage in repaired tissue. There is currently no widely accepted treatment for the repair of these lesions, except for total knee arthroplasty. Since the clinical introduction of autologous chondrocyte implantation by Brittberg and colleagues (1) as an alternative to mosaicplasty, many

have reported the clinical effectiveness of implanting autologous culture-expanded chondrocytes for cartilage regeneration (2). However, due to dedifferentiation or loss of reparative ability of chondrocytes during culture, the utility of transplanted chondrocytes is still unclear (3–5).

Stem cells, due to their ability to differentiate toward various lineages, have become an important tool in regenerative medicine and tissue engineering. Adult stem cells and progenitor cells for mesenchymal lineages from various tissues and organs, such as bone marrow (6), peripheral blood or blood vessels (7), adipose tissue (8), synovium (4), umbilical cord blood (9), and skeletal muscle (10), have been described. For cartilage regeneration and repair, stem cells are an attractive cell source due to their superior capacity for self-renewal, proliferation, and response to stress (11,12). Results of several studies have suggested that various stem cells have potential for cartilage regeneration and repair in experimental cartilage injury models (13–15). Recently, autologous stem cell–based tissue engineering has been used clinically for cartilage repair and regeneration (16,17). Our group has identified and isolated muscle-derived stem cells (MDSCs) from mouse skeletal muscle (12). MDSCs could potentially be a novel cell source for cartilage tissue engineering. They are known to have multilineage differentiation potential, including the ability to differentiate into skeletal muscle, bone, neural, endothelial, and hematopoietic tissue (12,18–23). We have previously shown that muscle-derived cells, including MDSCs, can undergo chondrogenesis *in vivo* and *in vitro* (24,25).

Variations in the characteristics of stem cells isolated from animals of different sexes have been recently investigated (26–28), and our group has demonstrated a sex difference in skeletal muscle regeneration and osteogenesis mediated by MDSCs (29,30). Therefore, we performed a series of experiments to examine whether there are differences in chondrogenic potential of male MDSCs (M-MDSCs) and female MDSCs (F-MDSCs) that could potentially influence their use in articular cartilage tissue engineering applications.

MATERIALS AND METHODS

MDSC isolation and culture. MDSCs were isolated from the hind limb skeletal muscle of 3-week-old C57.BL10 mice (The Jackson Laboratory, Bar Harbor, ME) via a modified preplate technique that has been described previously (10,31). The sex of the animals was determined anatomically at the time of isolation, and the sex of the cells was later confirmed by fluorescence *in situ* hybridization (FISH).

M-MDSC and F-MDSC populations were cultured on collagen-coated flasks in proliferation medium containing phenol red–free Dulbecco's modified Eagle's medium (DMEM; Invitrogen, San Diego, CA) supplemented with 110 mg/liter sodium pyruvate (Sigma-Aldrich, St. Louis, MO), 584 mg/liter L-glutamine, 10% fetal bovine serum, 10% horse serum, 1% penicillin/streptomycin (all from Invitrogen), and 0.5% chick embryo extract (Accurate, Westbury, NY). Cells were trypsinized and replated at a density of 250 cells/cm² until sufficient numbers of cells from all populations were available for the chondrogenic assays. All cells used in this study, except for cells examined with long-term culturing (described below), were passaged <30 times.

Characterization of MDSCs. Three M-MDSC populations (M1, M2, and M3) and 3 F-MDSC populations (F1, F2, and F3) were characterized by flow cytometry for CD34 and Sca1 expression. MDSCs were labeled with rat anti-mouse Sca1 (phycoerythrin) and CD34 (biotin) monoclonal antibodies (BD Biosciences, San Jose, CA). A separate portion of cells was treated with equivalent amounts of isotype control antibodies. Both fractions were washed and labeled with streptavidin–allophycocyanin; 7-aminoactinomycin D was added to exclude nonviable cells from analysis. Sca1 and CD34 expression was determined by flow cytometry with fluorescence-activated cell sorting (FACS) (FACSaria; Becton Dickinson, Mountain View, CA). Cell sex was confirmed by FISH with degenerate oligonucleotide-primed polymerase chain reaction (PCR)–labeled Y probes.

Retroviral transduction of MDSCs. M1 MDSCs and F1 MDSCs were retrovirally transduced with human bone morphogenetic protein 4 (BMP-4) and green fluorescent protein vector as described previously (32) and compared with nontransduced MDSCs for *in vitro* chondrogenesis by pellet culture (*n* = 3 of each sex). The transduced cells were cultured for 2 weeks before use in experiments, and the medium on these transduced cells was sampled to determine the level of transgene expression. The amount of BMP-4 secreted from the transduced cells was estimated with a BMP-4 bioassay, as previously described (33).

Purification of Sca1+ and Sca1– cells. Based on the significant difference in Sca1 expression between M-MDSCs and F-MDSCs, the Sca1+ and Sca1– fractions of BMP-4–transduced M1 and F1 populations were sorted by FACS (FACSaria), and each fraction was tested for chondrogenesis by pellet culture (*n* = 3 of each sex).

Population doublings. To compare short- and long-term proliferation potential, M-MDSCs and F-MDSCs were plated in 25-cm² collagen-coated flasks, and routine cell expansion was performed every 2–3 days. At each passage, cells were replated to a density of 225 cells/cm². The number of population doublings for each subculturing was calculated as the log₂ (N/N₀). This process was repeated for >150 population doublings. Karyotyping was performed as previously described (32), for 2 M-MDSC populations (M1 and M2) and 2 F-MDSC populations (F1 and F2). All populations of M-MDSCs and F-MDSCs that were expanded to 30 population doublings, 90 population doublings, and 150 population doublings were characterized by FACS, and chondrogenesis was assessed by pellet culture.

Pellet culture. Pellet culture was performed as described previously (34). Cells (2.5 × 10⁵) were centrifuged at 2,500 revolutions per minute for 5 minutes in 0.5 ml of




Figure 1. In vitro characterization of muscle-derived stem cells (MDSCs). **A**, Flow cytometric analysis of 6 MDSC populations (male MDSC [M-MDSC] 1–3 [M1–M3] and female MDSC [F-MDSC] 1–3 [F1–F3]). **B**, Quantification of the flow cytometric results, demonstrating that the percentage of Sca1+ cells was significantly higher in M-MDSCs than in F-MDSCs, with no significant difference between the 2 cell populations in the number of CD34+ cells. **C**, Measurement of the pellets produced by M-MDSCs and F-MDSCs (ruler is in mm). **D**, Alcian blue staining, demonstrating that pellets of M-MDSCs produced richer extracellular matrix-like hyaline cartilage than did F-MDSCs (original magnification $\times 200$; $\times 40$ in insets). Bars in **B** and **C** show the mean and SEM. * = $P < 0.05$; ** = $P < 0.01$.

standard chondrogenic medium containing DMEM supplemented with 1% penicillin/streptomycin, $10^{-7}M$ dexamethasone, 50 $\mu g/ml$ ascorbate-2-phosphate, 40 $\mu g/ml$ proline, 100 $\mu g/ml$ pyruvate, and insulin-transferrin-selenium (1% BD ITS+Premix; Becton Dickinson). The pellets in the experiments characterizing the BMP-4 response of MDSCs were cultured in chondrogenic medium supplemented with 10 ng/ml transforming growth factor $\beta 3$ (TGF $\beta 3$; R&D Systems, Minneapolis, MN), and those in experiments investigating Sca1 purification and population doublings were cultured in chondrogenic medium supplemented with 10 ng/ml TGF $\beta 3$ and 50 ng/ml BMP-4. Pellets were incubated at 37°C in 5% CO₂ for 14 days, and the medium was changed every 2–3 days.

Assessment of chondrogenesis. Pellets were fixed overnight in 10% neutral buffered formalin, dehydrated, embedded in paraffin, and sectioned in 5- μm -thick slices. Pellet sections were deparaffinized, placed in 3% acetic acid for 3 minutes, and transferred into Alcian blue solution for 30 minutes. The slides were rinsed with running tap water for 10 minutes and counterstained with nuclear fast red.

Quantitative real-time PCR analysis of pellet cultured cells. Messenger RNA was isolated using the RNeasy Plus Kit, according to the instructions of the manufacturer (Qiagen, Valencia, CA). After RNA extraction, quantitative real-time PCR analysis of all populations from different population doublings was carried out as previously described (35,36). Gene expression levels were calculated based on the difference in threshold cycle. All target genes were normalized to the housekeeping gene 18S; 18S primers and probes were designed by and purchased from Applied Biosystems (Foster City, CA). Primers and probes were designed for type II collagen, SOX9, and type X collagen, according to GenBank sequence. All target gene primers and probes were purchased from Integrated DNA Technologies (Coralville, IA). For quantitative PCR assays, the coefficient of variation calculated from triplicate assays was within 3%. Primers and probes were as follows: mouse type II collagen forward primer AAG-TCA-CTG-AAC-AAC-CAG-ATT-GAG-A, reverse primer AAG-TGC-GAG-CAG-GGT-TCT-TG, TaqMan probe ATC-CGC-AGC-CCC-GAC-GGC-T; mouse SOX9 forward primer CGG-CTC-CAG-CAA-GAA-CAA-G, reverse primer TGC-GCC-CAC-ACC-ATG-A, TaqMan probe ACG-TCA-AGC-GAC-CCA-TGA-ACG-C; mouse type X collagen forward primer TAC-TTA-CAC-GGA-TGG-AGA-CCA-TGT-T, reverse primer ATC-CAG-TTG-ACT-ACT-GGT-GCA-ATT-T, TaqMan probe AAC-CCT-CTT-TTC-GGA-TTA-ACC-CTG-CGA-GTT.

Articular cartilage defect model and cell transplantation. All animal experiments were approved by the Animal Research and Care Committee at Children's Hospital of Pittsburgh. Fifteen 12-week-old female nude rats (NIH-*Wm* NIH-RNU-M; Taconic, Germantown, NY) were used in this study. The animals were anesthetized by exposure to 3% isoflurane and O₂ gas (1.5 liter/minute) delivered through an inhalation mask. The knee joint was exposed by medial parapatellar incision, and the trochlear groove was exposed by lateral dislocation of the patella. A 1.8-mm outer diameter trephine drill was used to create bilateral osteochondral defects (1.8 $\times$ 2.0 mm) in the trochlear groove of each femur as previously described (25). BMP-4-transduced M1 MDSCs and F1 MDSCs (5×10^5) were mixed with fibrin glue

(Tisseel VH; Baxter Healthcare Hyland Immuno, Glendale, CA) and applied to the articular cartilage defect in both knees. As a control, fibrin glue without cells was used. After macroscopic examination, 5 distal femora in each group were dissected at weeks 4, 8, and 16 and embedded in paraffin. Specimens were stained with Safranin O-fast green, and the histologic grading scale described by O'Driscoll et al (37) was used to evaluate the quality of the repaired tissue.

Statistical analysis. Comparisons between 2 groups were performed using unpaired *t*-tests. Comparisons among 3 populations were performed by one-way analysis of variance except for comparisons of histologic scores, which were performed by Kruskal-Wallis analysis. Post hoc analysis was performed with Fisher's protected least significant difference test. *P* values less than 0.05 were considered significant.

RESULTS

In vitro MDSC characterization. Flow cytometric analysis with 6 populations demonstrated that the percentage of Sca1+ cells was significantly higher in M-MDSCs than in F-MDSCs (mean $\pm$ SEM 56.0 $\pm$ 15.4% versus 9.4 $\pm$ 1.9%) ($P < 0.05$), with no significant difference in the number of CD34+ cells (M-MDSCs 8.8 $\pm$ 4.5%, F-MDSCs 13.0 $\pm$ 6.6%) (Figures 1A and B). M-MDSCs also produced significantly larger pellets than F-MDSCs when cultivated in chondrogenic medium (mean $\pm$ SEM 1.06 $\pm$ 0.04 mm versus 0.85 $\pm$ 0.02 mm) ($P < 0.01$) (Figure 1C). Alcian blue staining demonstrated that pellets of M-MDSCs produced more extracellular matrix (ECM) that closely resembled hyaline-like cartilage, when compared with F-MDSCs (Figure 1D).

Effect of BMP-4 transduction and Sca1 purification on the chondrogenic potential of M- and F-MDSCs. Similar to the observations in nontransduced cells, BMP-4 transduction of M-MDSCs produced pellets with significantly larger diameter than was observed with BMP-4 transduction of F-MDSCs (mean $\pm$ SEM 1.30 $\pm$ 0.03 mm in BMP-4-transduced M-MDSCs, 1.05 $\pm$ 0.03 mm in nontransduced M-MDSCs, 0.94 $\pm$ 0.07 mm in BMP-4-transduced F-MDSCs, and 0.79 $\pm$ 0.05 mm in nontransduced F-MDSCs) ($P < 0.01$, BMP-4-transduced M-MDSCs versus nontransduced M-MDSCs; $P < 0.05$, BMP-4-transduced MDSCs versus BMP-4-transduced F-MDSCs; $P < 0.05$, nontransduced MDSCs versus nontransduced F-MDSCs) (Figure 2A). Alcian blue staining demonstrated that pellets of BMP-4-expressing M-MDSCs produced more ECM compared with F-MDSCs (Figure 2B).

Purification of Sca1+ M-MDSCs produced significantly larger pellets than were produced by Sca1-




Figure 2. Effects of bone morphogenetic protein 4 (BMP-4) transduction and Sca1 purification. **A**, Measurement of the chondrogenic pellets produced by BMP-4-transduced MDSCs (MDSC-B4) and nontransduced MDSCs. BMP-4-transduced M-MDSCs produced significantly larger chondrogenic pellets compared with nontransduced M-MDSCs and BMP-4-transduced F-MDSCs. **B**, Alcian blue staining, demonstrating that after BMP-4 transduction, the extracellular matrix (ECM) was richer in pellets of M-MDSCs compared with F-MDSCs (original magnification $\times 200$). **C**, Measurement of the chondrogenic pellets produced by Sca1+ and Sca1- MDSCs. In both male and female MDSCs, purified Sca1+ cells produced significantly larger pellets than Sca1- cells. **D**, Alcian blue staining, demonstrating that Sca1+ cells isolated from both male and female MDSCs produced richer ECM than the Sca1- cell fractions (original magnification $\times 200$; $\times 40$ in insets). Rulers in **A** and **C** are in mm; bars in **A** and **C** show the mean and SEM. * = $P < 0.05$; ** = $P < 0.01$. # = $P < 0.05$ versus female cells. See Figure 1 for other definitions.

M-MDSCs or by the Sca1+ and Sca1- fractions of F-MDSCs (mean $\pm$ SEM 1.29 ± 0.03 mm in Sca1+ M-MDSCs, 0.96 ± 0.05 mm in Sca1- M-MDSCs,

1.05 ± 0.07 mm in Sca1+ F-MDSCs, and 0.81 ± 0.03 mm in Sca1- F-MDSCs) ($P < 0.01$, Sca1+ M-MDSCs versus Sca1- M-MDSCs; $P < 0.05$, Sca1+ F-MDSCs




Figure 3. Effect of culturing on the chondrogenic potential of MDSCs. **A** and **B**, Numbers of population doublings (PDs) over time, and time required for population doubling. A decrease in population doubling times was observed with expansion of both male and female MDSCs. **C**, Quantitative results of flow cytometric analysis, demonstrating that the number of Sca1-expressing cells, at all population doublings, was significantly higher in M-MDSCs than in F-MDSCs. **D** and **E**, Measurement of chondrogenic pellets after 30, 90, and 150 population doublings (ruler is in mm). **F**, Alcian blue staining, demonstrating that M-MDSCs produced larger pellets with richer extracellular matrix compared with F-MDSCs at all population doublings, with decreased chondrogenic potential with cell expansion in both cell populations (original magnification $\times 200$; $\times 40$ in insets). **G**, Quantitative results of real-time polymerase chain reaction analysis, demonstrating significantly higher type II collagen (Col2) gene expression by M-MDSCs versus F-MDSCs at all population doublings, with a reduction in type II collagen expression with increasing population doubling. Bars in **B**, **C**, **E**, and **G** show the mean and SEM. * = $P < 0.05$; ** = $P < 0.01$. See Figure 1 for other definitions.

versus Sca1[−] F-MDSCs; $P < 0.05$, Sca1⁺ M-MDSCs versus Sca1⁺ F-MDSCs) (Figure 2C). Alcian blue staining revealed that the Sca1⁺ fraction of M-MDSCs produced more ECM than Sca1[−] M-MDSCs, as well as more ECM than either Sca1⁺ or Sca1[−] F-MDSCs (Figure 2D).

Influence of expansion on the chondrogenic potential of M- and F-MDSCs. Analysis of short-term kinetics showed that M-MDSC and F-MDSC popula-

tions had similar population doubling times over a 3-day period, as previously described (12). However, after moderate expansion over 14 days or extended expansion over 3 months (>150 population doublings), M-MDSC populations exhibited significantly shorter population doubling time than their female counterparts (mean $\pm$ SEM 24.6 ± 2.7 hours versus 38.5 ± 4.2 hours; $P < 0.01$) (Figures 3A and B). Flow cytometric analysis revealed that expression of Sca1 at all population doublings was




Figure 4. In vivo cartilage regeneration with bone morphogenetic protein 4 (BMP-4)-expressing MDSC treatment in the rat articular cartilage defect model. **A**, Macroscopic appearance, showing that the cartilage surface was partially filled at week 4, and the defect had become entirely covered by week 16, in the BMP-4-transduced MDSC (MDSC-B4)-treated group; however, a visible defect was still present in the BMP-4-transduced F-MDSC-treated group at all time points tested. **B**, Safranin O staining. At week 4, Safranin O-positive hyaline cartilage was observed in the defects in the group treated with BMP-4-expressing M-MDSCs, and the subchondral area was replaced by bone or cartilage, whereas fibrous tissue only partially filled the defects in the group treated with BMP-4-expressing F-MDSCs. Eight weeks after treatment, defects in the group treated with BMP-4-expressing F-MDSCs still exhibited partial healing and were covered with fibrous tissue, with minimal Safranin O-positive areas. In the group treated with BMP-4-expressing M-MDSCs, the defects were fully covered and well-integrated with cartilaginous tissue, which showed slight positivity for Safranin O. By week 16, treatment with BMP-4-expressing M-MDSCs had induced complete healing, with highly Safranin O-positive hyaline cartilage, whereas the group treated with BMP-4-expressing F-MDSCs showed incomplete healing, with limited Safranin O-positive hyaline cartilage. Larger images are higher-magnification views of the boxed areas (original magnification $\times 100$ in lower portion of each panel; $\times 40$ in upper portion of each panel with boxed area). **C**, O'Driscoll histologic scores. Scores in regenerated tissue from the BMP-4-expressing M-MDSC treatment group were significantly better than those in tissue from the BMP-4-expressing F-MDSC treatment group at 4, 8, and 16 weeks after transplantation. However, the F-MDSC treatment group showed significantly better scores than the control group. Bars show the mean and SEM. * = $P < 0.05$. See Figure 1 for other definitions.

significantly higher in M-MDSCs than in F-MDSCs (in male cells, mean $\pm$ SEM $64.7 \pm 17.1\%$, $73.7 \pm 8.3\%$, and $75.3 \pm 10.3\%$ at 30, 90, and 150 population doublings, respectively; in female cells, $10.0 \pm 3.3\%$, $2.7 \pm 1.2\%$, and $1.9 \pm 0.7\%$, respectively) ($P < 0.01$, M-MDSCs versus F-MDSCs at 90 and 150 population doublings; $P < 0.05$, M-MDSCs versus F-MDSCs at 30

population doublings) (Figure 3C). There was no significant difference in CD34 expression at all population doublings between M- and F-MDSCs (in male cells, $4.03 \pm 2.98\%$, $8.18 \pm 4.29\%$, and $35.50 \pm 21.88\%$ at 30, 90, and 150 population doublings, respectively; in female cells, $5.77 \pm 2.79\%$, $5.63 \pm 0.82\%$, and $11.47 \pm 3.81\%$, respectively).

Significantly larger pellets were produced with M-MDSCs than with F-MDSCs at all population doublings, with a decreasing trend over time (in male cells, mean $\pm$ SEM 1.16 ± 0.1 mm, 1.16 ± 0.08 mm, and 1.07 ± 0.06 mm at 30, 90, and 150 population doublings, respectively; in female cells, 0.91 ± 0.03 mm, 0.96 ± 0.04 mm, and 0.89 ± 0.02 mm, respectively) ($P < 0.05$, M-MDSCs versus F-MDSCs at all population doublings) (Figures 3D and E). Alcian blue staining also demonstrated that pellets of M-MDSCs showed decreasing production of ECM with passage, while F-MDSCs showed poor ECM production at all population doublings (Figure 3F).

Real-time PCR analysis demonstrated that type II collagen gene expression was significantly higher in M-MDSCs than in F-MDSCs; however, this trend decreased with increasing population doubling (in male cells, mean $\pm$ SEM 0.12 ± 0.092 , 0.0071 ± 0.0053 , and 0.000039 ± 0.000033 at 30, 90, and 150 population doublings, respectively; in female cells, 0.000026 ± 0.000050 , 0.000018 ± 0.000011 , and 0.0000071 ± 0.0000039 , respectively) ($P < 0.01$, M-MDSCs versus F-MDSCs at 30 and 90 population doublings) (Figure 3G). There were no differences in SOX9 or type X collagen gene expression between M-MDSCs and F-MDSCs at any population doubling (data not shown).

Cartilage regeneration. In the *in vivo* transplantation model, macroscopic assessment demonstrated that tissue was beginning to fill the cartilage surface at week 4, and the defect had become smooth and entirely covered by week 16 in the group treated with BMP-4-transduced M-MDSCs. However, a visible defect was present in the group treated with BMP-4-transduced F-MDSCs at all time points tested (Figure 4A).

Histologic assessment by Safranin O staining at week 4 demonstrated that defects in the group treated with BMP-4-expressing M-MDSCs contained Safranin O-positive hyaline cartilage and the subchondral area was replaced by bone or cartilage, whereas defects in the group treated with BMP-4-expressing F-MDSCs were partially filled with fibrous tissue (Figure 4B). Eight weeks after treatment, defects in the group treated with BMP-4-expressing F-MDSCs showed eburnated bone covered by thin fibrous tissue, with few Safranin O-positive areas. In contrast, defects in the group treated with BMP-4-expressing M-MDSCs were covered and well-integrated with cartilaginous tissue, which showed slightly positive staining with Safranin O (Figure 4B). At week 16, treatment with BMP-4-expressing M-MDSCs had induced good healing and the defect was covered with highly Safranin O-positive hyaline carti-

lage, whereas the BMP-4-expressing F-MDSC group showed incomplete healing and some Safranin O-positive hyaline cartilage limited to the border of the defect (Figure 4B). In the control group, there was no Safranin O-positive hyaline cartilage in the area of the defect at any time point up to 16 weeks after transplantation (Figure 4B).

O'Driscoll histologic scores in regenerated tissue from the group treated with BMP-4-expressing M-MDSCs were significantly better than those in the BMP-4-expressing F-MDSC treatment group at 4, 8, and 16 weeks after transplantation (Figure 4C). However, the F-MDSC treatment group showed significantly better scores than the control group (mean $\pm$ SEM histologic score at 4 weeks, 8 weeks, and 16 weeks, respectively, 15.2 ± 1.0 , 18.8 ± 0.5 , and 20.8 ± 1.0 in the group treated with BMP-4-expressing M-MDSCs; 12.0 ± 0.6 , 15.2 ± 1.0 , and 16.4 ± 1.2 in the group treated with BMP-4-expressing F-MDSCs; 9.6 ± 0.7 , 12.8 ± 1.0 , and 13.2 ± 0.8 in controls) ($P < 0.05$, M-MDSC-treated group versus F-MDSC-treated group and F-MDSC-treated group versus controls, at all time points) (Figure 4C).

DISCUSSION

To examine the difference in chondrogenic potential between M-MDSCs and F-MDSCs, we isolated MDSCs from 3 male and 3 female mice and tested these cells for chondrogenesis both *in vitro* and *in vivo*. MDSCs have previously been shown to have chondrogenic potential (24,25), especially after BMP-4 transduction. BMP-4 has also been demonstrated to enhance potential for chondrogenesis *in vitro* and *in vivo* in cell types other than MDSCs (38–40). It has also been reported that the combined effect of TGF β 3 and BMP-4 or BMP-2 on chondrogenic pellet size is greater than that of each growth factor administered separately (41,42). Consequently, we used TGF β 3 in all experiments, and BMP-4 was either added to the chondrogenic media or cells were retrovirally transduced to produce BMP-4 and cultured in chondrogenic media. Under these conditions, both M-MDSCs and F-MDSCs underwent chondrogenic differentiation. Interestingly, in experiments using chondrogenic media without BMP-4, M-MDSCs produced significantly larger pellets with richer ECM resembling hyaline-like cartilage compared with F-MDSCs. Our findings suggest that MDSCs can undergo chondrogenesis even without BMP-4, and that this phenomenon is more pronounced in M-MDSCs than F-MDSCs.

Various types of stem cells have been shown, by FACS analysis, to highly express Sca1, and these stem cells also have chondrogenic potential (43–45). Our group previously reported that MDSCs express the stem cell surface marker CD34 as well as Sca1 (10). Characterization by FACS analysis in the present study demonstrated that the number of Sca1+ cells was significantly higher in M-MDSCs than F-MDSCs; however, there was no significant difference in the number of CD34+ cells. We also compared the chondrogenic potential (pellet culture) of M-MDSC and F-MDSC populations sorted on the basis of Sca1 expression. In both M- and F-MDSCs, the Sca1+ fractions were more chondrogenic than the Sca1– fractions. In addition, the male Sca1+ cells showed substantially more chondrogenic potential in pellet culture than did female Sca1+ cells. Since M-MDSCs contain more Sca1+ cells than do F-MDSCs, we cannot exclude the possibility that the differential chondrogenic potential observed between M-MDSCs and F-MDSCs is related to the subpopulation of Sca1+ cells.

We have previously demonstrated the effect of BMP-4 on MDSC chondrogenesis in vitro and in vivo (25), and in the present study, we compared the differences in BMP-4 response of M-MDSCs and F-MDSCs, using a retroviral transduction method. BMP-4-transduced M-MDSCs produced significantly larger pellets with richer ECM than did pellets of BMP-4-transduced F-MDSCs.

When cultured in chondrogenic medium with TGF β 3 and BMP-4, M-MDSCs produced significantly larger pellets with richer ECM than did F-MDSCs, at all population doublings. The chondrogenic potential of M-MDSCs was maintained even after long-term culture (high population doubling), while the F-MDSCs lost their chondrogenic potential with expansion. Interestingly, real-time PCR analysis demonstrated that chondrogenic pellets of M-MDSCs showed significantly higher gene expression of type II collagen compared with F-MDSCs, even though all MDSCs (regardless of population doubling number) showed significantly decreasing expression with culturing. After 2 weeks in culture, there was weak expression of type X collagen and SOX9 in all pellets, but there was no significant difference in expression of these genes between M- and F-MDSCs. These findings indicate that M-MDSCs maintain a higher rate of self-renewal and have more chondrogenic potential than F-MDSCs at all population doublings, even though MDSCs of both sexes display a reduction of chondrogenic potential with culturing.

In an in vivo osteochondral defect model, treat-

ment with both M- and F-MDSCs demonstrated some ability to potentiate cartilage regeneration, adding to the findings of our previous study using only F-MDSCs (25). However, M-MDSC treatment led to greater cartilage regeneration than F-MDSC treatment. At week 16, macroscopic and histologic assessment demonstrated that treatment with BMP-4-transduced M-MDSCs produced good articular cartilage healing with highly Safranin O-positive hyaline cartilage. However, at 16 weeks, the BMP-4-transduced F-MDSC group still showed visible defects and only faintly Safranin O-positive hyaline cartilage, which was limited to the border of the defect. The histologic score at this time point was significantly better with BMP-4-transduced M-MDSC treatment compared with BMP-4-transduced F-MDSC treatment. Overall, in both in vivo and in vitro chondrogenic models, sex-related differences between M- and F-MDSCs were observed.

Sex differences in stem cell treatments for cartilage repair could have great clinical impact. OA is diagnosed more frequently in women than in men, especially in the population over 50 years old (46). Sex- and age-related differences in OA are well described and considered to be a key aspect of development and discovery of new treatments. Sex differences in knee geometry (47,48) and biomechanical properties (49) are well known, but it is not known if these differences contribute to the disparity in the prevalence of OA between men and women. Researchers have attempted to identify differences at the cellular level between OA in men and OA in women. Although the in vivo cartilage defect model used in the present study may not directly reflect OA progression, it does demonstrate the effectiveness of MDSCs in repairing full-thickness cartilage defects, which could possibly occur with OA. Although the role of host sex was not examined in this study, stem cell sex differences in healing of cartilage defects could lead to different clinical treatments of OA in men and women.

Some limitations of this study should be noted. First, we used murine muscle-derived cells, not human cells, and all male and female cells used in this study were from healthy mice. Results using cells from older human OA patients could be different. Second, although we demonstrated the chondrogenic potential of BMP-4-transduced MDSCs using in vitro and in vivo approaches, we did not test other BMPs, including BMP-2, BMP-6, or BMP-7. These BMPs could be investigated in the future.

In conclusion, our results suggest that M-MDSCs have higher chondrogenic potential in vitro and induce

more cartilage regeneration in an in vivo osteochondral defect model than do F-MDSCs. We also observed that M-MDSCs maintain their chondrogenic potential even at high population doublings, in contrast to observations with F-MDSCs. The fact that M-MDSCs contain a higher number of Sca1⁺ cells and maintain chondrogenic potential throughout the time of culturing may contribute to the observed sex difference in the chondrogenic potential of MDSCs. These results further the understanding of the chondrogenic potential of MDSCs and may contribute to the development of new therapeutic strategies for cartilage repair and regeneration.

ACKNOWLEDGMENTS

We would like to thank Burhan Gharaibeh and Jessica Tebbets for technical support. We are also grateful for assistance from James Cummins and Michele Keller.

AUTHOR CONTRIBUTIONS

Dr. Huard had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study design. Matsumoto, Kubo, Li, Fu, Huard.

Acquisition of data. Matsumoto, Kubo, Corsi, Li, Usas, Osawa.

Analysis and interpretation of data. Meszaros, Corsi, Cooper, Li, Usas, Osawa, Huard.

Manuscript preparation. Matsumoto, Meszaros, Corsi, Cooper, Li, Fu, Huard.

Statistical analysis. Matsumoto, Kubo, Meszaros, Cooper, Huard.

Project oversight. Huard.

REFERENCES

1. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 1994;331:889–95.
2. Browne JE, Anderson AF, Arciero R, Mandelbaum B, Moseley JB Jr, Micheli LJ, et al. Clinical outcome of autologous chondrocyte implantation at 5 years in US subjects. *Clin Orthop Relat Res* 2005;237–45.
3. Benz K, Breit S, Lukoschek M, Mau H, Richter W. Molecular analysis of expansion, differentiation, and growth factor treatment of human chondrocytes identifies differentiation markers and growth-related genes. *Biochem Biophys Res Commun* 2002;293:284–92.
4. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 2001;44:1928–42.
5. Richter W. Cell-based cartilage repair: illusion or solution for osteoarthritis. *Curr Opin Rheumatol* 2007;19:451–6.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
7. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. *J Cell Biol* 2001;153:1133–40.
8. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002;13:4279–95.
9. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. *Stem Cells* 2005;23:220–9.
10. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 2002;157:851–64.
11. Oshima H, Payne TR, Urish KL, Sakai T, Ling Y, Gharaibeh B, et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. *Mol Ther* 2005;12:1130–41.
12. Deasy BM, Gharaibeh BM, Pollett JB, Jones MM, Lucas MA, Kanda Y, et al. Long-term self-renewal of postnatal muscle-derived stem cells. *Mol Biol Cell* 2005;16:3323–33.
13. Wakitani S, Yamamoto T. Response of the donor and recipient cells in mesenchymal cell transplantation to cartilage defect. *Microsc Res Tech* 2002;58:14–8.
14. Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1994;76:579–92.
15. Koga H, Muneta T, Ju YJ, Nagase T, Nimura A, Mochizuki T, et al. Synovial stem cells are regionally specified according to local microenvironments after implantation for cartilage regeneration. *Stem Cells* 2007;25:689–96.
16. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* 2002;10:199–206.
17. Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage* 2007;15:226–31.
18. Cao B, Zheng B, Jankowski RJ, Kimura S, Ikezawa M, Deasy B, et al. Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential. *Nat Cell Biol* 2003;5:640–6.
19. Jankowski RJ, Deasy BM, Cao B, Gates C, Huard J. The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. *J Cell Sci* 2002;115(Pt 22):4361–74.
20. Lee JY, Qu-Petersen Z, Cao B, Kimura S, Jankowski R, Cummins J, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. *J Cell Biol* 2000;150:1085–100.
21. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J Clin Invest* 2002;110:751–9.
22. Shen HC, Peng H, Usas A, Gearhart B, Cummins J, Fu FH, et al. Ex vivo gene therapy-induced endochondral bone formation: comparison of muscle-derived stem cells and different subpopulations of primary muscle-derived cells. *Bone* 2004;34:982–92.
23. Wright V, Peng H, Usas A, Young B, Gearhart B, Cummins J, et al. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. *Mol Ther* 2002;6:169–78.
24. Adachi N, Sato K, Usas A, Fu FH, Ochi M, Han CW, et al. Muscle derived, cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects. *J Rheumatol* 2002;29:1920–30.
25. Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. *Arthritis Rheum* 2006;54:433–42.
26. Crisostomo PR, Markel TA, Wang M, Lahm T, Lillemoe KD, Meldrum DR. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. *Surgery* 2007;142:215–21.

27. Horner S, Pasternak G, Hehlmann R. A statistically significant sex difference in the number of colony-forming cells from human peripheral blood. *Ann Hematol* 1997;74:259–63.
28. Faiola B, Fuller ES, Wong VA, Pluta L, Abernethy DJ, Rose J, et al. Exposure of hematopoietic stem cells to benzene or 1,4-benzoquinone induces gender-specific gene expression. *Stem Cells* 2004;22:750–8.
29. Deasy BM, Lu A, Tebbets JC, Feduska JM, Schugar RC, Pollett JB, et al. A role for cell sex in stem cell-mediated skeletal muscle regeneration: female cells have higher muscle regeneration efficiency. *J Cell Biol* 2007;177:73–86.
30. Corsi KA, Pollett JB, Phillippi JA, Usas A, Li G, Huard J. Osteogenic potential of postnatal skeletal muscle-derived stem cells is influenced by donor sex. *J Bone Miner Res* 2007;22:1592–602.
31. Gharaibeh B, Lu A, Tebbets J, Zheng B, Feduska J, Crisan M, et al. Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. *Nat Protoc* 2008;3:1501–9.
32. Peng H, Usas A, Gearhart B, Young B, Olshanski A, Huard J. Development of a self-inactivating tet-on retroviral vector expressing bone morphogenetic protein 4 to achieve regulated bone formation. *Mol Ther* 2004;9:885–94.
33. Peng H, Chen ST, Wergedal JE, Polo JM, Yee JK, Lau KH, et al. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. *Mol Ther* 2001;4:95–104.
34. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* 1998;238:265–72.
35. Jadowiec J, Koch H, Zhang X, Campbell PG, Seyedain M, Sfeir C. Phosphorylation regulates the gene expression and differentiation of NIH3T3, MC3T3-E1, and human mesenchymal stem cells via the integrin/MAPK signaling pathway. *J Biol Chem* 2004;279:53323–30.
36. Jadowiec JA, Zhang X, Li J, Campbell PG, Sfeir C. Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the Smad pathway independent of bone morphogenetic protein. *J Biol Chem* 2006;281:5341–7.
37. O'Driscoll SW, Keeley FW, Salter RB. Durability of regenerated articular cartilage produced by free autogenous periosteal grafts in major full-thickness defects in joint surfaces under the influence of continuous passive motion: a follow-up report at one year. *J Bone Joint Surg Am* 1988;70:595–606.
38. Hatakeyama Y, Tuan RS, Shum L. Distinct functions of BMP4 and GDF5 in the regulation of chondrogenesis. *J Cell Biochem* 2004;91:1204–17.
39. Hoffman LM, Garcha K, Karamboulas K, Cowan MF, Drysdale LM, Horton WA, et al. BMP action in skeletogenesis involves attenuation of retinoid signaling. *J Cell Biol* 2006;174:101–13.
40. Sekiya I, Larson BL, Vuorio JT, Reger RL, Prockop DJ. Comparison of effect of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. *Cell Tissue Res* 2005;320:269–76.
41. Shirasawa S, Sekiya I, Sakaguchi Y, Yagishita K, Ichinose S, Muneta T. In vitro chondrogenesis of human synovium-derived mesenchymal stem cells: optimal condition and comparison with bone marrow-derived cells. *J Cell Biochem* 2006;97:84–97.
42. Semba I, Nonaka K, Takahashi I, Takahashi K, Dashner R, Shum L, et al. Positionally-dependent chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2. *Dev Dyn* 2000;217:401–14.
43. Zheng B, Cao B, Li G, Huard J. Mouse adipose-derived stem cells undergo multilineage differentiation in vitro but primarily osteogenic and chondrogenic differentiation in vivo. *Tissue Eng* 2006;12:1891–901.
44. Hachisuka H, Mochizuki Y, Yasunaga Y, Natsu K, Sharman P, Shinomiya R, et al. Flow cytometric discrimination of mesenchymal progenitor cells from bone marrow-adherent cell populations using CD34/44/45(–) and Sca-1(+) markers. *J Orthop Sci* 2007;12:161–9.
45. Yoshida S, Shimmura S, Nagoshi N, Fukuda K, Matsuzaki Y, Okano H, et al. Isolation of multipotent neural crest-derived stem cells from the adult mouse cornea. *Stem Cells* 2006;24:2714–22.
46. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. *Ann Intern Med* 2000;133:635–46.
47. Ding C, Cicuttini F, Scott F, Glisson M, Jones G. Sex differences in knee cartilage volume in adults: role of body and bone size, age and physical activity. *Rheumatology (Oxford)* 2003;42:1317–23.
48. Jones G, Glisson M, Hynes K, Cicuttini F. Sex and site differences in cartilage development: a possible explanation for variations in knee osteoarthritis in later life. *Arthritis Rheum* 2000;43:2543–9.
49. Csintalan RP, Schulz MM, Woo J, McMahon PJ, Lee TQ. Gender differences in patellofemoral joint biomechanics. *Clin Orthop Relat Res* 2002;260–9.

Blocking Vascular Endothelial Growth Factor With Soluble Flt-1 Improves the Chondrogenic Potential of Mouse Skeletal Muscle–Derived Stem Cells

Seiji Kubo,¹ Gregory M. Cooper,¹ Tomoyuki Matsumoto,¹ Julie A. Phillippi,² Karin A. Corsi,² Arvydas Usas,² Guangheng Li,² Freddie H. Fu,³ and Johnny Huard¹

Objective. To investigate the effect of vascular endothelial growth factor (VEGF) stimulation and the effect of blocking VEGF with its antagonist, soluble Flt-1 (sFlt-1), on chondrogenesis, using muscle-derived stem cells (MDSCs) isolated from mouse skeletal muscle.

Methods. The direct effect of VEGF on the in vitro chondrogenic ability of mouse MDSCs was tested using a pellet culture system, followed by real-time quantitative polymerase chain reaction (PCR) and histologic analyses. Next, the effect of VEGF on chondrogenesis within the synovial joint was tested, using genetically engineered MDSCs implanted into rat osteochondral defects. In this model, MDSCs transduced with a retroviral vector to express bone morphogenetic protein 4 (BMP-4) were coimplanted with MDSCs transduced to express either VEGF or sFlt-1 (a VEGF antagonist) to provide a gain- and loss-of-function experimental design. Histologic scoring was used to compare cartilage formation among the treatment groups.

Results. Hyaline-like cartilage matrix production was observed in both VEGF-treated and VEGF-blocked (sFlt-1-treated) pellet cultures, but quantitative PCR revealed that sFlt-1 treatment improved the expression of chondrogenic genes in MDSCs that were stimulated to undergo chondrogenic differentiation with BMP-4 and transforming growth factor β 3 (TGF β 3). In vivo testing of articular cartilage repair showed that VEGF-transduced MDSCs caused an arthritic change in the knee joint, and sFlt-1 improved the MDSC-mediated repair of articular cartilage, compared with BMP-4 alone.

Conclusion. Soluble Flt-1 gene therapy improved the BMP-4- and TGF β 3-induced chondrogenic gene expression of MDSCs in vitro and improved the persistence of articular cartilage repair by preventing vascularization and bone invasion into the repaired articular cartilage.

Articular cartilage is an avascular tissue with a limited intrinsic capacity for regeneration. For this reason, tissue engineering techniques to repair articular cartilage have been extensively studied, and chondrocyte transplantation already has become a clinical reality (1–3).

For the repair of large cartilage defects caused by osteoarthritis or rheumatoid arthritis, stem cells are more attractive than primary chondrocytes because of their superior capacity for self renewal, proliferation, and resistance to stress (4–6). Several studies have suggested that stem-like cells can undergo chondrogenesis and repair articular cartilage in experimental cartilage-injury models, including studies using muscle-derived stem cells (MDSCs) (7–11). Stem cells have recently been used clinically for cartilage repair (12,13).

However, problems still surround the use of stem

Supported by the US Department of Defense (contract W81XWH-08-0076), the NIH (grant R01-DE-13420-06), and the Hirtzel Foundation. Dr. Huard's work was supported by the William F. and Jean W. Donaldson Chair at the Children's Hospital of Pittsburgh, and the Henry J. Mankin Endowed Chair for Orthopaedic Research at the University of Pittsburgh.

¹Seiji Kubo, MD, PhD, Gregory M. Cooper, PhD, Tomoyuki Matsumoto, MD, PhD, Johnny Huard, PhD: Children's Hospital of Pittsburgh, and University of Pittsburgh, Pittsburgh, Pennsylvania; ²Julie A. Phillippi, PhD, Karin A. Corsi, PhD, Arvydas Usas, MD, Guangheng Li, MD, PhD: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; ³Freddie H. Fu, MD: University of Pittsburgh, Pittsburgh, Pennsylvania.

Dr. Huard has received consulting fees, speaking fees, and/or honoraria from Cook Myosite, Inc. (more than \$10,000).

Address correspondence and reprint requests to Johnny Huard, PhD, Children's Hospital of Pittsburgh, 4100 Rangos Research Center, 3705 Fifth Avenue, Pittsburgh, PA 15213-2582. E-mail: jhuard@pitt.edu.

Submitted for publication October 1, 2007; accepted in revised form September 17, 2008.

cells to repair cartilage. One of the most important issues is the control of vascular endothelial growth factor (VEGF) signaling during the chondrogenic differentiation of stem cells. Previous research has shown that VEGF treatment prevents condensation of chondrogenic mesenchyme during early limb bud development, through abnormal vascularization (14). The expression of high levels of VEGF in the terminal stages of chondrogenesis leads to endochondral ossification through angiogenesis (15,16). Also, VEGF has been shown to enhance endochondral bone formation elicited by bone morphogenetic protein (BMP)-transduced MDSCs in a model of ectopic bone formation (17). VEGF expression by chondrocytes in osteoarthritic joints may be related to cartilage destruction (18–24). Furthermore, high doses of VEGF may induce the onset and progression of arthritis (25–27). This theory is supported by studies showing that treatment with soluble Flt-1 (sFlt-1), a VEGF antagonist, decreased the progression of arthritis in a mouse model (28,29). Taken together, these results suggest that VEGF may be a catabolic molecule for cartilage. Contrary to this interpretation, VEGF has been shown to be necessary for chondrocyte survival during cartilage development. In VEGF-deficient mouse models, massive cell death was observed in the joint and epiphyseal regions of cartilage during cartilage development (30,31).

Despite these paradoxical results, the effects of VEGF on stem cell-mediated chondrogenesis *in vitro* and on cartilage repair *in vivo* have not been rigorously investigated. Our current study used a gain- and loss-of-function approach based on gene therapy techniques to ascertain the role of VEGF in stem cell-mediated cartilage repair. MDSCs were genetically engineered to express human BMP-4, human VEGF₁₆₅, or the VEGF antagonist, sFlt-1. These cells were used to test the effect of VEGF on MDSC-mediated cartilage repair in the knee joint in an *in vivo* osteochondral defect model.

This study was designed to test the hypothesis that increased VEGF expression within a healing osteochondral defect will inhibit the persistence of cartilage repair, and that blocking VEGF signaling using sFlt-1 will improve the quality and persistence of MDSC-mediated cartilage regeneration. The effects on chondrogenesis of VEGF stimulation and blocking VEGF signaling with sFlt-1 were studied, not only with respect to the intrinsic chondrogenic capacity of stem cells, but also within the more complex *in vivo* environment that includes interactions with synovia, subchondral bone, and adjacent cartilage in the knee joint.

MATERIALS AND METHODS

Isolation of primary MDSCs. MDSCs were isolated from the hind limb skeletal muscle of 3-week-old male C57BL/10J mice (The Jackson Laboratory, Bar Harbor, ME) via a modified preplate technique that has been described previously (5).

Retroviral transduction. Retroviral vectors expressing human BMP-4 (retro-BMP-4), VEGF (retro-VEGF), or sFlt-1 (retro-sFlt-1) were generated by replacing the U3 region in the 5' long terminal repeat with the human cytomegalovirus promoter, as previously described (8,17). MDSCs were transduced separately with these retroviral vectors at a multiplicity of infection of 5 in the presence of Polybrene (8 $\mu\text{g}/\text{ml}$). The transduced cells were expanded for 2 weeks before being used in experiments, and conditioned medium was sampled to determine transgene expression.

The level of BMP-4 secreted from the transduced cells was estimated with a BMP-4 bioassay, as previously described (32). The levels of VEGF or sFlt-1 secreted from the transduced cells were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN).

In vitro chondrogenesis. Pellet culturing was performed as described previously (33). Cell pellets were made with the following: 1) 1.4×10^5 nontransduced MDSCs and 1.4×10^5 BMP-4-expressing MDSCs (B4 group), 2) 1.4×10^5 VEGF-expressing MDSCs and 1.4×10^5 BMP-4-expressing MDSCs (B4+VEGF group), 3) 1.4×10^5 sFlt-1-expressing MDSCs and 1.4×10^5 BMP-4-expressing MDSCs (B4+sFlt-1 group), and 4) 2.8×10^5 primary chondrocytes derived from the mouse knee (Chond group). Three more groups (groups 5, 6, and 7) were created using 2.8×10^5 nontransduced MDSCs. Pellets from groups 1–4 were cultured in 0.5 ml of chondrogenic medium that contained Dulbecco's modified Eagle's medium supplemented with 1% penicillin/streptomycin, $10^{-7}M$ dexamethasone, 50 $\mu\text{g}/\text{ml}$ ascorbate-2-phosphate, 40 $\mu\text{g}/\text{ml}$ proline, 100 $\mu\text{g}/\text{ml}$ pyruvate, and 1% ITS+ Premix (Becton Dickinson, Franklin Lakes, NJ) with 10 ng/ml of transforming growth factor β_3 (TGF β_3 ; R&D Systems). Group 5 pellets (made with nontransduced cells) were cultured in chondrogenic medium without the TGF β_3 supplement (C group). Group 6 pellets were fed with chondrogenic medium without TGF β_3 but with 50 ng/ml BMP-4 added (C+B4 group). Finally, group 7 pellets were fed with chondrogenic medium supplemented with 10 ng/ml of TGF β_3 (C+T group). All pellets were incubated at 37°C in 5% CO₂, and the medium was changed every 2–3 days. Pellets were harvested after 7, 14, and 28 days in culture.

Alcian blue staining. Pellets were fixed overnight in 10% neutral buffered formalin, dehydrated, embedded in paraffin, and sectioned in 5- μm -thick slices. Pellet sections were deparaffinized, placed in 3% acetic acid for 3 minutes, and transferred into Alcian blue solution for 30 minutes. The slides were then rinsed with running tap water for 10 minutes and counterstained with nuclear fast red.

Real-time quantitative polymerase chain reaction (PCR) analysis of pellet culture cells. Messenger RNA was isolated using the RNeasy Plus Kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. After RNA extraction, real-time quantitative PCR analysis was carried out as described previously (34,35). Gene expression levels were

calculated based on the difference in threshold cycle (ΔC_t) method (separate tubes). All target genes were normalized to the reference housekeeping gene, *18S*. *18S* primers and probes were designed by and purchased from Applied Biosystems (Foster City, CA). Primers and probes were designed for type II collagen, SOX9, and type X collagen, according to the GenBank sequence. All target gene primers and probes were purchased from Integrated DNA Technologies Inc. (Coralville, IA).

Each experimental value is reported as the mean $\pm$ SEM results of triplicate treatments. For quantitative PCR assays, the coefficient of variation (CV) was calculated from 3 assay replicates. For all treatment groups and target genes analyzed, the CV did not exceed 3%. One-way analysis of variance, followed by Tukey-Kramer's post hoc test, was performed to determine significance among treatment groups. *P* values less than 0.05 were considered significant.

Repair of osteochondral defects. The policies and procedures of our animal laboratory are in accordance with those published by the US Department of Health and Human Services. The research techniques used for these experiments were approved by the Animal Research and Care Committee at Children's Hospital of Pittsburgh. Twenty-eight 10-week-old nude rats (NIH-*Wistar* NIH-RNU-M; Taconic, Germantown, NY) were used in this study. The rats were anesthetized via exposure to 3% isoflurane and O_2 gas (1.5 liter/minute) delivered through an inhalation mask. The knee joint was exposed by the medial parapatellar approach, and the trochlear groove was exposed by lateral dislocation of the patella. A 1.8-mm outer diameter trephine drill was used to create an osteochondral defect (1.8×2.0 mm) in the trochlear groove of each femur. MDSCs isolated from mouse skeletal muscle were mixed with fibrin glue (Tisseel VH; Baxter Healthcare, Glendale, CA) before transplantation.

The rats were divided into 7 treatment groups. The defects in group 1 rats (no-cell control) were treated with acellular fibrin glue, defects in group 2 rats (MDSC group) were treated with 500,000 MDSCs embedded in fibrin glue, defects in group 3 rats (VEGF group) were treated with 250,000 MDSC-VEGF cells plus 250,000 MDSCs embedded in fibrin glue, defects in group 4 rats (sFlt-1 group) were treated with 250,000 MDSC-sFlt-1 cells plus 250,000 MDSCs embedded in fibrin glue, defects in group 5 rats (B4 group) were treated with 250,000 MDSC-B4 cells plus 250,000 MDSCs embedded in fibrin glue, defects in group 6 rats (B4+VEGF group) were treated with 250,000 MDSC-B4 cells plus 250,000 MDSC-VEGF cells embedded in fibrin glue, and defects in group 7 rats (B4+sFlt-1 group) were treated with 250,000 MDSC-B4 cells plus 250,000 MDSC-sFlt-1 cells embedded in fibrin glue. Four defects (in 2 rats) were made for each group ($n = 4$ knees per group). The rats were allowed to move freely within their cages after surgery. Rats were killed 8 weeks or 16 weeks after surgery. Groups of rats that received VEGF treatment were killed 8 weeks after surgery because the deterioration of the knee joint impaired the ability of the rats to move freely.

Histologic evaluation of cartilage repair. After qualitative macroscopic examination, 4 distal femora per group per time point were dissected and fixed with 10% neutral buffered formalin for 48 hours, followed by decalcification with 10%

EDTA for 2 weeks and paraffin embedding. Sagittal sections, 5 μ m in thickness, were obtained from the center of each defect and stained with Safranin O-fast green. The histologic grading scale described by Sellers et al (36) was used to evaluate the quality of the repaired tissue. All data are expressed as the mean $\pm$ SD. Differences in each category and the total score were analyzed by Kruskal-Wallis and Mann-Whitney U tests, using SPSS software, version 12.0.1 (SPSS, Chicago, IL). *P* values less than 0.05 were considered significant.

RESULTS

Expression of BMP-4, VEGF, and sFlt-1 by transduced MDSCs. To ensure that we had successfully transduced the cells and induced protein secretion, we tested the supernatant collected from transduced or nontransduced cells, using either an activity bioassay (for BMP) or an ELISA (for VEGF and sFlt-1). MDSCs transduced with retro-BMP-4 secreted 327 ng/ 10^6 cells/24 hours, as detected by BMP-4 bioassay. MDSCs transduced with retro-VEGF secreted human VEGF at a mean $\pm$ SD rate of 1.14 ± 0.05 μ g/ 10^6 cells/24 hours, compared with nontransduced MDSCs, which secreted mouse VEGF at a rate of 750 ± 12.2 pg/ 10^6 cells/24 hours. Retro-sFlt-1-transduced MDSCs secreted sFlt-1 at a level of 2.1 ± 0.004 ng/ 10^6 cells/24 hours.

In a separate set of experiments, 2.5×10^5 transduced or nontransduced cells were cultured in 3-dimensional micromass pellet culture for 48 hours, the medium was collected, and VEGF expression was tested using an ELISA. Medium from nontransduced MDSC pellets contained 409.0 ± 49.4 (mean $\pm$ SD) ng/ml of VEGF, which was significantly more than primary chondrocytes (226.7 ± 53.8 ng/ml) and significantly less than cells transduced to express BMP-4 (B4 cells; 592.9 ± 52 ng/ml).

Effect of VEGF and sFlt-1 on chondrogenic differentiation of MDSCs. Histologic analysis was used to determine whether the different mixtures of transduced and nontransduced cells were capable of undergoing chondrogenic differentiation in vitro. Histologic analysis of tissues stained with Alcian blue showed that all of the pellets from every group contained some well-differentiated, round chondrocytic cells and also showed some level of hyaline-like cartilage extracellular matrix (ECM) production, as evidenced by positive Alcian blue staining (Figure 1A). Nontransduced control MDSCs (group C; Figure 1A) showed the least intense staining, whereas primary chondrocytes (Chond group; Figure 1A) showed the largest amount of Alcian blue-positive ECM. Pellets from the B4+VEGF group showed evi-




Figure 1. A, Alcian blue staining of pellets. Hyaline cartilage-like Alcian blue-positive matrix was observed in pellets created with chondrocytes (Chond) or with muscle-derived stem cells (MDSCs) transduced to express bone morphogenetic protein (BMP-4; B4), a mixture of cells expressing BMP-4 or vascular endothelial growth factor (VEGF; B4+VEGF), and in pellets with a mixture of cells expressing BMP-4 or soluble Flt-1 (sFlt-1; B4+sFlt-1). Nontransduced cells (C) with BMP-4 (C+B4) or transforming growth factor β 3 (C+T) added to the medium did not show similar matrix formation. Chondrocyte-like round cells were observed in all groups in which cells were transduced (B4, B4+sFlt-1, B4+VEGF) and at all time points (days 7, 14, and 28) but not in control pellet cultures (C, C+B4, C+T). The pellets cultured with BMP-4 plus sFlt-1 contained more chondrocyte-like cells at all time points compared with the other groups. (Original magnification $\times 100$.) B–E, Results of quantitative polymerase chain reaction performed on cells cultured in 3-dimensional micromass pellet culture. Pellets created with a mixture of MDSCs expressing BMP-4 or sFlt-1 (B4+sFlt-1) demonstrated significantly higher type II collagen and SOX9 gene expression than other groups at all time points in culture. Type X collagen expression was significantly higher in the B4+sFlt-1 group compared with the B4+VEGF group at 7 days and 28 days. Type I collagen expression was highest in the B4+VEGF group at all time points. Bars show the mean and SEM.

dence of chondrogenesis peripherally, with a region of fibrous, noncartilaginous tissue near the center of the pellet, especially after 28 days in culture (B4+VEGF group; Figure 1A). Together, these results suggest that neither VEGF nor sFlt-1 inhibits the intrinsic chondrogenic capacity of MDSCs.

In order to assess the expression of several chondrogenic marker genes under different in vitro experimental conditions, we performed quantitative PCR analysis. Pellets from the B4+sFlt-1 group showed significantly greater type II collagen and SOX9 gene expression than the groups treated with BMP-4 or

BMP-4 plus VEGF at all time points, and showed higher type X collagen gene expression than the B4+VEGF group at 7 days and 28 days (Figures 1B–D). The B4+VEGF group showed significantly higher type II collagen gene expression than the B4 group at 14 days (Figure 1B). It was also observed that the expression of type II collagen decreased over time in the B4+sFlt-1 group; however, a similar trend was observed in the primary chondrocyte control pellets (Figure 1B). Type I collagen expression increased over time in the B4, B4+VEGF and Chond groups but remained constant in the group treated with B4+sFlt-1 (Figure 1E).




Figure 2. **A,** Macroscopic images of osteochondral defects 8 weeks after transplantation. Grossly, the defects treated with either BMP-4 or a mixture of BMP-4- and sFlt-1-expressing cells appeared more similar to the surrounding cartilage. Both groups treated with VEGF showed evidence of cartilage destruction. **B,** Photomicrographs showing Safranin O staining of defect areas 8 weeks postoperatively. Large areas of Safranin O-positive cartilage were noted in defects treated with BMP-4. Although the defects treated with VEGF plus BMP-4 showed Safranin O-positive cartilage, damage in other regions of the joint was observed. Each photomicrograph shows both a high-magnification view (original $\times 200$; top) and a lower-magnification view (original $\times 50$; bottom). See Figure 1 for definitions.

Effect of VEGF treatment on progression of arthritis in the knee joint. In order to generally assess the effects of our different treatments, we performed a

qualitative gross analysis of the knee joint at 8 weeks or 16 weeks postoperatively. Eight weeks after surgery, the B4+VEGF group showed the appearance of arthritis




Figure 3. **A**, Macroscopic images of osteochondral defects 16 weeks after transplantation. Grossly, the defects treated with BMP-4 appeared to be healed with cartilaginous tissue that resembled the surrounding articular cartilage. **B**, Photomicrographs showing Safranin O staining of defect areas 16 weeks postoperatively. Both groups treated with BMP-4-expressing cells showed some Safranin O-positive tissue in the defect region. The defects treated with a mixture of cells expressing either BMP-4 or sFlt-1 (B4+sFlt-1) showed the best repair of tissue, based on histologic analysis. Each photomicrograph shows both a high-magnification view (original $\times 200$; top) and a lower-magnification view (original $\times 50$; bottom). See Figure 1 for definitions.




Figure 4. **A**, Total histologic scores for samples analyzed 8 weeks after surgery. Scores were significantly lower in the B4 and B4+sFlt-1 groups compared with all other treatment groups and were significantly higher in the B4+VEGF group compared with all other groups. **B**, Total histologic scores for samples analyzed 16 weeks after surgery. Statistical analysis of the total scores showed that the group treated with BMP-4 plus sFlt-1 had significantly lower scores than all other groups tested. Bars show the mean and SD. * = $P < 0.05$. See Figure 1 for definitions.

progression (Figure 2A). In the VEGF-treated group, similar arthritis progression was observed. Groups that were not treated with cells expressing VEGF showed no signs of arthritis 8 weeks after surgery (Figure 2A). Defects in the B4, B4+VEGF, or B4+sFlt-1 group showed good coverage by cartilaginous tissue that was well integrated with the surrounding cartilage. Defects in groups that were not treated with BMP-4-expressing cells were covered by connective tissue, and the surfaces of those defects were concave compared with surrounding normal convex cartilage (Figure 2A). Between 8 weeks and 16 weeks after surgery, the knees treated with cells expressing VEGF showed high levels of joint destruction, inhibiting normal movement of the rats. Therefore, rats in the VEGF or B4+VEGF group were removed from the study before the 16-week postoperative time point.

Sixteen weeks after transplantation, defects that were not treated with BMP-4-expressing cells appeared to be rough, and the margin between the defects and the surrounding cartilage could be clearly identified (Figure 3A). Defects in the B4 or B4+sFlt-1 group still contained smooth repaired tissue that was well integrated with the surrounding cartilage. However, the group treated with BMP-4 showed some mild cartilage erosion (Figure 3A).

Improved cartilage formation in the sFlt-1-treated group, by Safranin O staining. We used Safranin O staining to highlight the glycosaminoglycan content in the repaired region as an indicator of overall cartilage health. Eight weeks after transplantation, defects in the B4 or B4+sFlt-1 group contained Safranin O-positive hyaline cartilage, and the subchondral area was replaced by bone or cartilage. In contrast, defects in groups that were not treated with BMP-4-expressing cells (no cell control, MDSC only, VEGF, and sFlt-1 groups) were covered and filled with undifferentiated mesenchymal tissue or fibrous tissue (Figure 2B). Groups treated with VEGF-expressing cells showed evidence of mild destruction, including pannus invasion, osteolysis, and cyst formation in subchondral bone area, although the B4+VEGF group did show Safranin O-positive hyaline cartilage repair near the articular surface.

Sixteen weeks after transplantation, defects in the control group showed eburnated bone covered by thin fibrous tissue (Figure 3B). The MDSC-treated defects showed undifferentiated fibrous tissue, while the B4+sFlt-1 group showed the presence of cartilaginous tissue that stained slightly positive with Safranin O. The defects in the B4 and B4+sFlt-1 groups were covered by Safranin O-positive cartilage, although the B4 group showed less Safranin O-positive cartilage compared with the B4+sFlt-1 group.

Table 1. Histologic scores for cartilage repair at 8 weeks and 16 weeks after surgery*

Group	Filling of defect	Integration to adjacent tissue	Safranin O staining	Cellular morphology	Architecture within defect	Architecture of surface	Subchondral bone replacement	Tidemark formation	Total score
8 weeks									
Control	1.25 ± 0.5	0.50 ± 0.6	4.00 ± 0.0	5.00 ± 0.0	0.25 ± 0.5	1.75 ± 0.5	3.00 ± 0.8	4.00 ± 0.0	19.75 ± 1.7
MDSCs	0.75 ± 1.0	0.00 ± 0.0	3.25 ± 0.5	4.50 ± 0.6	0.25 ± 0.5	1.00 ± 0.8	3.50 ± 0.6	4.00 ± 0.0	17.25 ± 1.7
VEGF	2.50 ± 1.0	2.50 ± 0.6	4.00 ± 0.0	5.00 ± 0.0	3.00 ± 0.8	2.50 ± 1.0	4.00 ± 0.0	4.00 ± 0.0	27.50 ± 2.5
sFlt-1	1.50 ± 0.6	0.00 ± 0.0	3.25 ± 0.5	4.75 ± 0.5	0.75 ± 1.0	1.25 ± 0.5	3.00 ± 1.2	3.50 ± 0.6	18.00 ± 2.6
BMP-4	0.00 ± 0.0	0.00 ± 0.0	0.75 ± 0.5	2.00 ± 0.0	0.00 ± 0.0	1.00 ± 0.0	1.50 ± 1.3	3.75 ± 0.5	9.00 ± 1.6
BMP-4+VEGF	0.00 ± 0.0	1.25 ± 1.0	1.75 ± 1.0	2.50 ± 1.3	3.50 ± 1.0	2.50 ± 1.0	4.00 ± 0.0	3.50 ± 1.0	19.00 ± 2.2
BMP-4+sFlt-1	0.00 ± 0.0	0.00 ± 0.0	1.75 ± 1.3	1.50 ± 1.0	0.00 ± 0.0	0.75 ± 1.0	1.75 ± 1.3	2.00 ± 0.8	7.75 ± 4.4
16 weeks									
Control	3.25 ± 1.0	2.00 ± 1.2	4.00 ± 0.0	5.00 ± 0.0	3.00 ± 2.0	1.50 ± 0.6	4.00 ± 0.0	4.00 ± 0.0	26.75 ± 4.3
MDSCs	1.75 ± 1.0	0.00 ± 0.0	3.50 ± 0.6	5.00 ± 0.0	1.25 ± 1.9	1.50 ± 0.6	4.00 ± 0.0	4.00 ± 0.0	21.00 ± 2.7
sFlt-1	0.75 ± 0.5	0.00 ± 0.0	3.00 ± 0.8	4.75 ± 0.5	0.00 ± 0.0	1.25 ± 1.0	3.75 ± 0.5	3.50 ± 0.6	17.00 ± 3.4
BMP-4	0.50 ± 1.0	0.50 ± 0.6	2.50 ± 0.6	3.00 ± 0.8	0.00 ± 0.0	1.25 ± 0.5	3.00 ± 0.0	3.00 ± 0.8	13.75 ± 1.9
BMP-4+sFlt-1	0.00 ± 0.0	0.00 ± 0.0	1.50 ± 0.6	0.50 ± 0.6	0.00 ± 0.0	1.00 ± 0.0	1.25 ± 1.0	1.50 ± 0.6	5.75 ± 1.7

* Values are the mean ± SD. The histologic grading scale described by Sellers et al (36) was used to evaluate the quality of the repaired tissue. The total score ranges from 0 (normal articular cartilage) to 31 (no repair). MDSCs = muscle-derived stem cells; VEGF = vascular endothelial growth factor; sFlt-1 = soluble Flt-1; BMP-4 = bone morphogenetic protein 4.

Usefulness of blocking VEGF in cartilage repair, as supported by histologic scoring. We evaluated articular cartilage repair semiquantitatively, using a previously described histologic grading system, in order to better characterize the types of tissue that formed within the defects. In this system, 7 histologic categories (filling of defect, integration to adjacent tissue, Safranin O staining, cellular morphology, architecture within defect, architecture of surface, subchondral bone replacement, and tidemark formation) are evaluated and scored. The total score ranges from 0 (normal articular cartilage) to 31 (no repair) (36).

In general, 8 weeks after implantation, defects treated with BMP-4 showed improved healing compared with defects that were not treated with BMP-4 (Figure 4A and Table 1). Among the groups treated with BMP-4, defects that were also treated with cells expressing sFlt-1 (B4+sFlt-1) showed the lowest scores, suggesting that the repaired cartilage was most histologically normal in this group.

The total score for the B4+sFlt-1 group was significantly lower (histologically more similar to normal, undamaged cartilage) than that for all other groups (Figures 4A and B and Table 1). The total score for the B4 group was lower than that for the control group, the MDSC group, and the sFlt-1-only group. Also, the total score for the sFlt-1 group was lower than that for the control group.

DISCUSSION

VEGF signaling has been shown to play important roles during endochondral bone formation, apopto-

sis, osteophyte formation, and cartilage destruction in the osteoarthritic joint (15,16,18–24). Furthermore, VEGF has been shown to be one of the most important factors that can cause arthritis (25–27). These data support the idea that VEGF is related to cartilage destruction. However, it also has been shown that VEGF is important for stem cell and chondrocyte survival during limb bud development (30,31), and that blocking VEGF signaling can suppress BMP-4-induced endochondral bone formation by MDSCs (17). Therefore, the role of VEGF during stem cell-mediated chondrogenesis needs to be better understood.

To gain insight into the paradoxical effects of VEGF, in the current study, we first tested the in vitro chondrogenic ability of MDSCs, using a 3-dimensional pellet culture system in chondrogenic medium with 10 ng/ml of TGFβ3. Using this system, it was possible to determine the direct effect of VEGF on the intrinsic capacity of MDSCs to undergo chondrogenic differentiation. Specifically, the system enabled the determination of whether VEGF secretion by differentiated chondrocytes can cause intrinsic cartilage resorption, and whether inhibition of VEGF signaling by sFlt-1 could prevent chondrogenic differentiation of MDSCs. Hyaline cartilage-like matrix production was observed by histologic evaluation of pellets from the group treated with BMP-4 plus VEGF, as evidenced by Alcian blue-positive staining after 7, 14, and 28 days in culture (Figure 1A). Also, it was observed that coculture of VEGF-expressing cells with BMP-4-expressing cells did not alter the expression of chondrogenic genes (type II

collagen, type X collagen, and SOX9) compared with culture with BMP-4 alone (Figures 1B and C).

These results suggest that VEGF does not prevent the chondrogenic differentiation of BMP-4-transduced MDSCs in pellet culture after stimulation with chondrogenic medium containing 10 ng/ml of TGF β 3. These results seem to be in agreement with previous studies of the effect of VEGF on micromass culture of mesenchymal cells from the chicken limb bud (14). More importantly, it was observed that the presence of sFlt-1-expressing cells within the pellets further enhanced the chondrogenic differentiation of BMP-4-expressing MDSCs at all time points, as shown both histologically (Figure 1A) and by gene expression (Figures 1B and C). These results suggest that blocking VEGF with sFlt-1 does not prevent *in vitro* chondrogenesis of BMP-4-transduced MDSCs in pellet culture but, in fact, improves the expression of chondrogenic marker genes by MDSCs induced to undergo chondrogenic differentiation. Although sFlt-1 does not block the expression of VEGF by MDSCs, it blocks VEGF activity after it is secreted, suggesting either a potential beneficial effect of blocking VEGF activity on chondrogenesis or that sFlt-1 influences chondrogenesis through an unknown mechanism independent of VEGF.

In addition, this study used an *in vivo* transplantation experiment to provide information about the effect of VEGF on the BMP-4-induced chondrogenic ability of MDSCs, using a gain- and loss-of-function experimental design. MDSCs were exposed to the more stressful environment of the synovial joint, where matrix production is normally strongly suppressed. Furthermore, a complete assessment of healing can be obtained in this model, because the local environment in which cartilage regeneration must be elicited was preserved.

Eight weeks after surgery, the BMP-4-treated groups, regardless of the presence or absence of VEGF activity, showed better cartilage repair macroscopically on the surface of the defect than groups not treated with BMP-4 (Figure 2A). By Safranin O staining, the repaired tissue seemed to resemble hyaline cartilage (Figure 2B). The difference in the histologic scores between the 3 BMP-4-treated groups was mostly attributable to pannus invasion into the subchondral region and osteolysis of the subchondral bone, which affected the histologic scores for "architecture within defect" and "subchondral bone formation" (Figure 2B and Table 1). This result suggests that even in the synovial joint, VEGF will not prevent the BMP-4-induced chondrogenesis mediated by MDSCs, but that VEGF can cause osteolysis and pannus invasion through the activation of

cells related to osteolysis and synovial hypertrophy. However, the VEGF-treated groups were given markedly worse total scores than groups that had no VEGF treatment or received sFlt-1 treatment (Table 1). Interestingly, when comparing the group treated with BMP-4 plus VEGF with the VEGF group, osteophyte formation was seen only in the group that received BMP-4 plus VEGF, although both groups commonly showed arthritis development, including an increased amount of joint fluid, synovial hypertrophy, and pannus invasion into cartilage and bone (Figures 2A and B). Regardless of the presence or absence of BMP-4 treatment, the results suggest that treatments for articular cartilage repair that involve VEGF should be avoided.

Sixteen weeks after surgery, the BMP-4-treated groups showed improved healing, both macroscopically and microscopically, compared with the groups that were not treated with BMP-4 (Figure 3B and Table 1). This result supports a previous report by our group (8). In addition, the group treated with BMP-4 plus sFlt-1 showed significantly better histologic scores compared with the group treated with BMP-4 only, which resulted from improved scores in the "cellular morphology," "subchondral bone formation," and "tidemark formation" categories. These scores were affected by the invasion of bone into regions that were cartilaginous 8 weeks after surgery (Figures 3A and B). The improved, but suboptimal, repair of cartilage through the addition of BMP-expressing cells has been suggested in previous reports (37). The inhibition of vascular invasion by sFlt-1 could be a factor that led to improved scores in these categories. Moderate osteophyte formation was observed only in the BMP-4 group. It is possible that endogenous VEGF expression combined with BMP-4 treatment might play a role in the formation of osteophytes as time progresses.

The results of the current study are consistent with those of previous studies demonstrating that VEGF triggers cartilage destruction (18–24). Furthermore, this study suggests that the destruction observed following the implantation of VEGF-expressing cells was caused by extrinsic environmental changes rather than via direct effects on chondrogenic differentiation of the implanted MDSCs. This hypothesis is supported by the observation that the addition of VEGF did not inhibit MDSCs from undergoing chondrogenic differentiation *in vitro* (Figure 1).

In contrast, sFlt-1 improves BMP-4- and TGF β 3-induced chondrogenic gene expression of MDSCs *in vitro* and improves the persistence of articular cartilage repair by preventing angiogenesis that can lead to the

invasion of bone into cartilage. However, in this study, no differences were observed between any of the groups in the histologic score for "architecture of surface." This result suggests that growth factors other than BMP or VEGF are needed to fully repair cartilage at the articular surface. In conclusion, sFlt-1 treatment combined with BMP-4 treatment of MDSCs is a potential therapy for cartilage repair that may improve the quality and persistence of articular cartilage repair.

ACKNOWLEDGMENTS

We thank Dr. Ryosuke Kuroda for animal experiment guidance and Mr. David Humiston for editing the manuscript.

AUTHOR CONTRIBUTIONS

Dr. Huard had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study design. Kubo, Cooper, Phillippi, Usas, Li, Fu, Huard.

Acquisition of data. Kubo, Matsumoto, Corsi, Li.

Analysis and interpretation of data. Kubo, Cooper, Matsumoto, Phillippi, Corsi, Usas, Li, Huard.

Manuscript preparation. Kubo, Cooper, Corsi, Usas, Li, Fu, Huard.

Statistical analysis. Kubo, Cooper, Matsumoto, Huard.

REFERENCES

1. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 1994;331:889–95.
2. Ochi M, Uchio Y, Kawasaki K, Wakitani S, Iwasa J. Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee. *J Bone Joint Surg Br* 2002;84:571–8.
3. Visna P, Pasa L, Cizmar I, Hart R, Hoch J. Treatment of deep cartilage defects of the knee using autologous chondrograft transplantation and by abrasive techniques: a randomized controlled study. *Acta Chir Belg* 2004;104:709–14.
4. Oshima H, Payne TR, Urish KL, Sakai T, Ling Y, Gharaibeh B, et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. *Mol Ther* 2005;12:1130–41.
5. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 2002;157:851–64.
6. Deasy BM, Gharaibeh BM, Pollett JB, Jones MM, Lucas MA, Kanda Y, et al. Long-term self-renewal of postnatal muscle-derived stem cells. *Mol Biol Cell* 2005;16(7):3323–33.
7. Adachi N, Sato K, Usas A, Fu FH, Ochi M, Han CW, et al. Muscle derived, cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects. *J Rheumatol* 2002;29:1920–30.
8. Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. *Arthritis Rheum* 2006;54:433–42.
9. Wakitani S, Yamamoto T. Response of the donor and recipient cells in mesenchymal cell transplantation to cartilage defect. *Microsc Res Tech* 2002;58:14–8.
10. Koga H, Muneta T, Ju YJ, Nagase T, Nimura A, Mochizuki T, et al. Synovial stem cells are regionally specified according to local microenvironments after implantation for cartilage regeneration. *Stem Cells* 2007;25:689–96.
11. Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1994;76:579–92.
12. Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage* 2007;15:226–31.
13. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. *Cell Transplant* 2004;13:595–600.
14. Yin M, Pacifici M. Vascular regression is required for mesenchymal condensation and chondrogenesis in the developing limb. *Dev Dyn* 2001;222:522–33.
15. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nat Med* 1999;5:623–8.
16. Carlevaro MF, Cermelli S, Cancedda R, Descalzi Cancedda F. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. *J Cell Sci* 2000;113(Pt 1):59–69.
17. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J Clin Invest* 2002;110:751–9.
18. Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. *Arthritis Rheum* 1998;41:1632–8.
19. Hashimoto S, Creighton-Achermann L, Takahashi K, Amiel D, Coutts RD, Lotz M. Development and regulation of osteophyte formation during experimental osteoarthritis. *Osteoarthritis Cartilage* 2002;10:180–7.
20. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, et al. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. *Am J Pathol* 2003;162:171–81.
21. Tanaka E, Aoyama J, Miyauchi M, Takata T, Hanaoka K, Iwabe T, et al. Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. *Histochem Cell Biol* 2005;123:275–81.
22. Pufe T, Petersen W, Tillmann B, Mentlein R. The splice variants VEGF₁₂₁ and VEGF₁₈₉ of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. *Arthritis Rheum* 2001;44:1082–8.
23. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. *J Pathol* 2004;202:367–74.
24. Pufe T, Lemke A, Kurz B, Petersen W, Tillmann B, Grodzinsky AJ, et al. Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. *Am J Pathol* 2004;164:185–92.
25. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. *Blood* 2006;108:1849–56.
26. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. *Histol Histopathol* 2002;17:961–72.

27. Matsumoto Y, Tanaka K, Hirata G, Hanada M, Matsuda S, Shuto T, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. *J Immunol* 2002;168:5824–31.
28. De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. *J Immunol* 2003;171:4853–9.
29. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. *Gene Ther* 2003;10:1950–60.
30. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. *Development* 2004;131:2161–71.
31. Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. *Development* 2000;127:1445–53.
32. Peng H, Chen ST, Wergedal JE, Polo JM, Yee JK, Lau KH, et al. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. *Mol Ther* 2001;4:95–104.
33. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* 1998;238:265–72.
34. Jadowiec J, Koch H, Zhang X, Campbell PG, Seyedain M, Sfeir C. Phosphoryn regulates the gene expression and differentiation of NIH3T3, MC3T3-E1, and human mesenchymal stem cells via the integrin/MAPK signaling pathway. *J Biol Chem* 2004;279:53323–30.
35. Jadowiec JA, Zhang X, Li J, Campbell PG, Sfeir C. Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the Smad pathway independent of bone morphogenetic protein. *J Biol Chem* 2006;281:5341–7.
36. Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1997;79:1452–63.
37. Gelse K, von der Mark K, Aigner T, Park J, Schneider H. Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells. *Arthritis Rheum* 2003;48:430–41.